# DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop: S2-25-26 Baltimore, Maryland 21244-1850



# **State Demonstrations Group**

January 14, 2020

Mr. Dave Richard North Carolina Department of Health and Human Services 2001 Mail Service Center Raleigh, NC 27699-2001

Dear Mr. Richard:

The Centers for Medicare & Medicaid Services (CMS) has approved North Carolina's evaluation design for the section 1115 demonstration entitled "North Carolina Medicaid Reform Demonstration" (Project Number 11-W00313/4) effective through October 31, 2024. We sincerely appreciate the state's commitment to a rigorous evaluation approach of your initiative.

CMS has added the approved evaluation design to the demonstration's Special Terms and Conditions (STCs) as part of Attachment C. A copy of the STCs, that includes the new attachment, is enclosed with this letter per 42 CFR 431.424(c). The approved evaluation design may now be posted to the state's Medicaid website within thirty days of CMS approval. CMS will also post the approved evaluation design as a standalone document separate from the STCs on Medicaid.gov.

Please note that an interim evaluation report, consistent with this approved evaluation design, is due to CMS one year prior to the expiration of the demonstration, or at the time of the renewal application if the state chooses to extend the demonstration. Likewise, a summative evaluation report, consistent with this approved design, is due to CMS within 18 months of the end of the demonstration period.

We look forward to our continued partnership with you and your staff on the North Carolina Medicaid Reform Demonstration. If you have any questions, please contact your CMS project officer, Ms. Sandra Phelps. Ms. Phelps may be reached by email at <a href="mailto:Sandra.Phelps@cms.hhs.gov">Sandra.Phelps@cms.hhs.gov</a>.

# Sincerely,

/s/

Danielle Daly
Director
Division of Demonstration
Monitoring and Evaluation

Angela D. Garner Director Division of System Reform Demonstrations

# Enclosure

ce: Bill Brooks, Director DMFO South – CMCS Shantrina Roberts, Deputy Director DMFO South – CMCS

# North Carolina Medicaid Reform Demonstration Updated Evaluation Design Report: Incorporating CMS Feedback Received on June 17, 2019 and October 24, 2019 November 7, 2019

### A. General Background Information

North Carolina's 1115 waiver entitled "North Carolina Medicaid Reform Demonstration" was approved by the Centers for Medicare & Medicaid Services (CMS) on October 24, 2018. This evaluation embeds two major elements of the demonstration: components related to the Medicaid and Health Choice delivery system in NC and components to address the State's needs related to the opioid use epidemic and general substance use treatment needs. The Substance Use Disorder (SUD) component began on July 1, 2019 and will expire on October 31, 2023. The remaining components of the waiver will begin no sooner than February 1, 2020 and will expire on October 31, 2024.

Plans for the waiver were initiated in 2015, when the NC General Assembly enacted Session Law 2015-245 to move the state's Medicaid and Health Choice programs away from reimbursing providers directly through fee for service payments to a system of paying private health plans on a capitated basis. The purpose of the NC 1115 Waiver is to improve Medicaid beneficiary health outcomes through the implementation of a new delivery system, to enhance the viability and sustainability of the NC Medicaid program by maximizing the receipt of high-value care, and to reduce substance use disorders statewide.

There are several large components to NC's 1115 demonstration, which are listed in Table 1. First, the State intends to transition most NC Medicaid and Health Choice enrollees into a capitated model of care from the fee-for-service system that exists in the state currently. This will be done in phases, by eligible populations. The first group will transition to Prepaid Health Plans (PHPs) beginning February 1, 2019. This group will consist of individuals statewide, who are not excluded from enrollment in PHPs and do not qualify for one of the behavioral health intellectual / developmental disability tailored plans ("BH I/DD Tailored Plans") or specialized foster care plans, described below. Later in the demonstration, Medicaid enrollees with severe behavioral health conditions, intellectual or developmental disabilities, and/or traumatic brain injuries who meet criteria established by the Department of Health and Human Services and current and former foster care youth¹ will be enrolled in separate capitated plans with specialized features that are customized for the needs of each of these groups. While most Medicaid enrollees will be covered under a capitated plan under the demonstration, several groups are excluded from participation, including Medicaid enrollees dually eligible for

<sup>&</sup>lt;sup>1</sup> Medicaid only beneficiaries in foster care under age 21, children in adoptive placements and former foster youth who aged out of care up to age 26

Medicare<sup>2</sup>, Medicaid enrollees who are eligible through the Medically Needy program, those with limited eligibility such as through family planning waivers, those presumptively eligible for Medicaid, and prison inmates receiving Medicaid covered inpatient services. In addition, Medicaid-only beneficiaries receiving long-stay nursing home services and Community Alternatives Program for Children and Community Alternatives Program for Disabled Adults enrollees are also excluded.

Table 1: Major components of the 1115 waiver demonstration and implemention dates

Component	Current	Description of	Medicaid and
	implementation date	Implementation	Health Choice Beneficiaries affected
Enhancement of benefits related to substance use disorder (SUD) treatments	July 1, 2019		All receiving SUD services
Standard Plans (SPs)	February 1, 2020	Statewide implementation	All standard plan enrollees <sup>3</sup>
Advanced Medical Homes	February 1, 2020	Many primary care practices are already certified as AMH; Others will become certified after PHP launch	All receiving primary care from an AMH
Enhanced Case Management and Other Services (ECMOS) Pilots	Late 2020	Pilots will begin delivering services to eligible PHP enrollees in selected regions	PHP enrollees in selected pilot regions in need of pilot services (only SP enrollees affected at launch)
Behavioral Health and Intellectual/Developmental Disability Tailored Plans and Statewide Foster Care Plan	2021		All enrollees in a BH I/DD Tailored Plan or the

-

<sup>&</sup>lt;sup>2</sup> Dual eligibles will enroll in BH I/DD Tailored Plans at their launch for BH and I/DD services only and that medically needy and HIPP beneficiaries who are enrolled in the Innovations waiver will enroll in BH I/DD Tailored Plans at their launch.

<sup>&</sup>lt;sup>3</sup> Does not include indiiduals who qualify for a BH I/DD Tailored Plan or the Statewide Foste Care Plan or those excluded from managed care (e.g., Dual eligible, Medically Need, those receiving limited benefits). Eligibility criteria for BH I/DD Tailored Plans can be found <a href="here">here</a>. DHHS is in the process of establishing eligibility criteria for the Statewide Foster Care Plan.

Component	Current implementation date	Description of Implementation	Medicaid and Health Choice Beneficiaries affected
			Statewide Foster Care Plan <sup>4</sup>
Health Homes	2021	On launch of BH I/DD Tailored Plans	Those eligible for a TP who are in a participating practice

The second major component of the 1115 waiver demonstration involves the enhancement of benefits related to substance use disorder services, allowing the state to leverage federal financial participation for additional services to treat opioid use disorders and other substance use disorders. These newly covered services include services for substance use disorders (SUDs) provided to Medicaid enrollees who are short-term residents in residential and inpatient treatment facilities that previously were excluded from federal Medicaid payments because of the institution for mental diseases (IMD) exclusion, as well as other improvements in access to and standards of SUD care. The expansions in covered SUD services could affect all Medicaid and Health Choice enrollees with SUDs by increasing the covered treatment options available, but also by increasing access to SUD services broadly (new as well as existing services), potentially creating more capacity in service provision due to shifts to more appropriate care.

A third major component of NC's demonstration is the Advanced Medical Home (AMH) program. Building on its well-established primary care case-management program, the AMH will be used as a primary mechanism for delivering and coordinating care management services under managed care. PHPs will be required to deliver care management services and are mandated to contract with all "Tier 3" AMHs (further described below) for the provision of care management to many enrollees. The Department expects that 22 percent of beneficiaries will receive care management services through AMHs or PHPs (https://files.nc.gov/ncdma/Care-Management-Rate-Memo-20190724.pdf). These individials will be identified by risk stratification tools, which are further described below. Providers can continue to receive fees as they did under the primary care case management program or can take on additional care management responsibilities in exchange for higher levels of reimbursement to be negotiated with the PHPs. The AMH program distinguishes practices by tiers, according to their care management responsibilities. As defined in the AMH manual for primary care providers (https://files.nc.gov/ncdma/documents/Providers/Programs Services/amh/AMH Provider-Manual 08272018.pdf): "In AMH Tier 1 and 2 practices, PHPs will retain primary responsibility for care management, and practices will be required to closely coordinate and interact with each PHP with which they have a contract. AMH Tier 3 is a more advanced phase for practices

-

<sup>&</sup>lt;sup>4</sup> Eligibility criteria for BH I/DD Tailored Plans can be found <u>here.</u> DHHS is in the process of establishing eligibility criteria for the Statewide Foster Care Plan.

ready to take on care management responsibility, either alone or as part of a network of practices affiliated with a Clinically Integrated Network (CIN). PHPs will provide oversight for care management delivered in or on behalf of Tier 3 practices, but will otherwise delegate day to day care management responsibilities to the Tier 3 AMH practice or the system or CIN/partners with which they are affiliated." The distinction between Tier 1 and Tier 2 practices follows the same distinction from the current primary care case management program, with Tier 2 practices required to contract with a regional network, on top of the Tier 1 practice requirements such as after-hours availability and panel size. PHPs are required to contract with 100% of Tier 3 AMH practices in their service area. As of March 2019, there are already almost 2,800 practices which have been certified as AMHs, and almost 1,500 of these have been certified as AMH Tier 3 practices. The majority of PHP enrollees are expected to be served in an AMH of level 1-3.

Finally, NC's demonstration permits DHHS to establish a limited number of Enhanced Case Management and Other Services (ECMOS) Pilots in a subset of regions. These pilots will offer reimbursement for evidence-based, non-medical interventions that address housing, transportation, food, and interpersonal safety and toxic stress that are traditionally not covered by Medicaid. North Carolina will be able to evaluate the impact of the provision of these services on enrollees' health outcomes and healthcare costs. The Pilots will be evaluated in a separate evaluation plan, although Pilot participants will be identified in some of the analyses for the overall waiver.

### B. Evaluation Hypotheses and Research Questions

There are three stated goals of the demonstration:

- Measurably improve health outcomes via a new delivery system
- Maximize high-value care to ensure sustainability of the Medicaid program, and
- Reduce Substance Use Disorder (SUD)

The primary and secondary drivers, or pathways through which these goals will be achieved, are diagrammed below. Goal 3 is additionally broken out in more detail in the subsequent figure.

The primary drivers for both Goals 1 and 2 include an increased use of alternative payment models, providing care with a whole person orientation, enhanced access to care, and more use of evidence-based practices and medicines.

The use of alternative payment models is expected to increase through the use of prepaid health plans and provider-led entities (PHPs/PLEs), rather than the current Medicaid system. Contracts with PHPs/PLEs were developed assuming a slower growth rate, which thus incentivizes the plans to manage costs. PHPs and PLEs are permitted to use APMs to pay providers, which differs from the current design. Additionally, PHPs have more ability to place incentives upon providers to meet quality expectations. Likewise, the PHPs and PLEs are held

to quality expectations and other oversight/compliance by the State; this puts more emphasis on quality and value than existed prior to the waiver.

It is well known that medical care is only responsible for a fraction of a person's health; other factors like social determinants of health and the environment are also considerable drivers. An increased emphasis on a whole person orientation will improve beneficiary outcomes. A number of managed care initiatives specifically address social determinants of health; these include the ECMOS Pilots (and the spread of learning from those pilots), the resource platform linking needs to local assets, and mandated screening for patients' SDOH-related needs.


Multiple secondary drivers will improve the use of evidence-based practices (EBP). This driver is deliberately worded to account for both the recommendation of EBPs by providers as well as the ability and willingness of patients to participate in the EBP - ability to access recommended care (e.g. transportation needs met), trust in the provider's recommendation through shared decision-making, and adherence to the recommended treatment (e.g. medication). Some of the secondary drivers are focused on the provider side (e.g. quality improvement activity and shared data/transparency) while others are more focused on the patient and family (patient engagement, use of advanced medical homes). Likewise, oversight of the PHPs and providers will increase the practice of EBPs, and access to the resource platform will attenuate social barriers inhibiting patients' abilities to access evidence-based practices.

Finally, these primary drivers also improve the ability of patients to access care more generally. These will improve provider satisfaction and willingness to treat and manage Medicaid beneficiaries. As providers become more satisfied with the Medicaid program, more providers will be willing to manage Medicaid beneficiaries and many will increase the number of Medicaid beneficiaries they are able to manage.


Goal 3 is "reduce substance use disorder." In the driver diagrams below, we provide additional detail on this goal - reduce the burden of substance use disorder, including mortality and morbidity. The primary design of the SUD element of the waiver is to more effectively provide beneficiaries with substance use disorders the high-quality care they need and reduce the long-term use of opiods.

The Goal 3-specific Driver Diagram focuses on drivers uniquely leading to Goal 3. Secondary drivers of better management, integration between physical and behavioral health, patient satisfaction with SUD treatment and an increase in MAT prescribers lead to treatment being provided in the most appropriate care setting, adherence to medications and SUD services (including, as above, the notion that providers need to be recommending EBPs as well), and improving rates of treatment and engagement with SUD treatment and providers.

# **DRIVER DIAGRAM: GOALS 1 & 2**



#### **DRIVER DIAGRAM: GOAL 3**



Each of the three goals leads to a number of hypotheses which will be tested in the demonstration evaluation through the related research questions. These include:

## Goal 1: Measurably improve health outcomes via a new delivery system

**Hypothesis 1.1** The implementation of Medicaid managed care will increase access to health care and improve the quality of care and health outcomes.

Research question 1.1.a Does the implementation of standard plans increase access to health care for those in the target population?

Research question 1.1.b Does the implementation of standard plans improve the quality of health care received by the target population?

Research question 1.1.c Does the implementation of standard plans improve health outcomes for those in the target population?

Research question 1.1.d Does the implementation of BH I/DD Tailored Plans increase access to health care for those in the target population?

Research question 1.1.e Does the implementation of BH I/DD Tailored Plans improve the quality of health care received by the target population?

Research question 1.1.f Does the implementation of BH I/DD Tailored Plans improve health outcomes for those in the target population?

Research question 1.1.g Does the implementation of specialized foster care plans increase access to health care for those in the target population?

Research question 1.1.h Does the implementation of specialized foster care plans improve the quality of health care received by the target population?

Research question 1.1.i Does the implementation of specialized foster care plans improve health outcomes for those in the target population?

**Hypothesis 1.2**: The implementation of Medicaid managed care will increase the rate of use of behavioral health services at the appropriate level of care and improve the quality of behavioral health care received.

Research question 1.2.a Does the implementation of standard plans increase the rate of use of behavioral health services at the appropriate level of care for those in the target population?

Research question 1.2.b Does the implementation of standard plans improve the quality of behavioral health care received for those in the target population?

Research question 1.2.c Does the implementation of BH I/DD Tailored Plans increase the rate of use of behavioral health services at the appropriate level of care for those in the target population?

Research question 1.2.d Does the implementation of BH I/DD Tailored Plans improve the quality of behavioral health care received for those in the target population?

Research question 1.2.e Does the implementation of specialized foster care plans increase the rate of use of behavioral health services at the appropriate level of care for those in the target population?

Research question 1.2.f Does the implementation of specialized foster care plans improve the quality of behavioral health care received for those in the target population?

**Hypothesis 1.3**: The implementation of Medicaid managed care will increase the use of medication-assisted treatment (MAT) and other opioid treatment services and decrease the long-term use of opioids.

Research question 1.3.a Does the implementation of standard plans increase the use of MAT for those in the target population?

Research question 1.3.b Does the implementation of standard plans increase the use of non-medication opioid treatment services for those in the target population?

Research question 1.3.c Does the implementation of standard plans decrease the probability of long-term use of opioids?

Research question 1.3.d Does the implementation of BH I/DD Tailored Plans increase the use of MAT for those in the target population?

Research question 1.3.e Does the implementation of BH I/DD Tailored Plans increase the use of non-medication opioid treatment services for those in the target population?

Research question 1.3.f Does the implementation of BH I/DD Tailored Plans decrease the probability of long-term use of opioids?

Research question 1.3.g Does the implementation of specialized foster care plans increase the use of MAT for those in the target population?

Research question 1.3.h Does the implementation of specialized foster care plans increase the use of non-medication opioid treatment services for those in the target population?

Research question 1.3.i Does the implementation of specialized foster care plans decrease the probability of long-term use of opioids?

**Hypothesis 1.4**: Implementation of Advanced Medical Homes (AMHs) and Health Homes (HHs) will increase the delivery of care management services and will improve quality of care and health outcomes.

Research question 1.4.a Does the implementation of AMHs and HHs increase the probability of receiving care management services?

Research question 1.4.b Does the implementation of AMHs and HHs improve the quality of care received?

Research question 1.4.c Does the implementation of AMHs and HHs improve health outcomes?

**Hypothesis 1.5**: The implementation of Medicaid managed care will reduce disparities (increase equity) in the quality of care received across rurality, age, race/ethnicity and disability status.

Research question 1.5.a Does the implementation of standard plans increase equity in the quality of care for those in the target population?

Research question 1.5.b Does the implementation of BH I/DD Tailored Plans increase equity in the quality of care for those in the target population?

Research question 1.5.c Does the implementation of specialized foster care plans increase equity in the quality of care for those in the target population?

### Goal 2: Maximize high-value care to ensure sustainability of the Medicaid program

**Hypothesis 2.1**: The implementation of Medicaid managed care will decrease the use of emergency departments for non-urgent use and hospital admissions for ambulatory sensitive conditions.

Research question 2.1.a Does the implementation of standard plans decrease the use of emergency departments for non-urgent use?

Research question 2.1.b Does the implementation of standard plans decrease the use of hospital admissions for ambulatory sensitive conditions?

Research question 2.1.c Does the implementation of BH I/DD Tailored Plans decrease the use of emergency departments for non-urgent use?

Research question 2.1.d Does the implementation of BH I/DD Tailored Plans decrease the use of hospital admissions for ambulatory sensitive conditions?

Research question 2.1.e Does the implementation of specialized foster care plans decrease the use of emergency departments for non-urgent use?

Research question 2.1.f Does the implementation of specialized foster care plans decrease the use of hospital admissions for ambulatory sensitive conditions?

**Hypothesis 2.2:** The implementation of Medicaid managed care will increase the number of enrollees receiving care management, overall and during transitions in care.

Research question 2.2.a Does the implementation of standard plans increase the number of enrollees receiving care management?

Research question 2.2.b Does the implementation of standard plans increase the number of enrollees receiving care management during transitions in care?

Research question 2.2.c Does the implementation of BH I/DD Tailored Plans increase the number of enrollees receiving care management?

Research question 2.2.d Does the implementation of BH I/DD Tailored Plans increase the number of enrollees receiving care management during transitions in care?

Research question 2.2.e Does the implementation of specialized foster care plans increase the number of enrollees receiving care management?

Research question 2.2.f Does the implementation of specialized foster care plans increase the number of enrollees receiving care management during transitions in care?

**Hypothesis 2.3**: The implementation of Medicaid managed care will reduce Medicaid program expenditures.

Research question 2.3.a Does the implementation of standard plans reduce Medicaid program expenditures?

Research question 2.3.b Does the implementation of BH I/DD Tailored Plans reduce Medicaid program expenditures?

Research question 2.3.c Does the implementation of specialized foster care plans reduce Medicaid program expenditures?

**Hypothesis 2.4**: The implementation of Medicaid managed care will increase provider satisfaction and participation in the Medicaid program.

Research question 2.4.a Does the implementation of standard plans increase provider satisfaction?

Research question 2.4.b Does the implementation of standard plans increase provider participation in the Medicaid program?

Research question 2.4.c Does the implementation of BH I/DD Tailored Plans increase provider satisfaction?

Research question 2.4.d Does the implementation of BH I/DD Tailored Plans increase provider participation in the Medicaid program?

Research question 2.4.e Does the implementation of specialized foster care plans increase provider satisfaction?

Research question 2.4.f Does the implementation of specialized foster care plans increase provider participation in the Medicaid program?

# **Goal 3: Reduce Substance Use Disorder (SUD)**

**Hypothesis 3.1**: Expanding coverage of SUD services to include residential services furnished in IMDs as part of a comprehensive strategy for treating SUD will result in improved care quality and outcomes for patients with SUD.

Research question 3.1.a Does the expanded coverage of SUD services increase the quality of care for patients with SUD?

Research question 3.1.b Does the expanded coverage of SUD services improve outcomes for people with SUD?

**Hypothesis 3.2:** Expanding coverage of SUD services to include residential services furnished in institutions for mental diseases (IMDs) as part of a comprehensive strategy for treating SUD will increase the use of MAT and other appropriate opioid treatment services and decrease the long-term use of prescription opioids.

Research question 3.2.a Does the expanded coverage of SUD services increase the use of MAT?

Research question 3.2.b Does the expanded coverage of SUD services increase the use of non-medication opioid treatment services at the appropriate level of care?

Research question 3.2.c Does the expanded coverage of SUD services decrease the probability of long-term use of opioids?

**Hypothesis 3.3:** Expanding coverage of SUD services will result in no changes in total Medicaid and out-of-pocket costs for people with SUD diagnoses, increases in Medicaid costs on SUD IMD services, increases in SUD pharmacy, outpatient, and rehabilitative costs, and decreases in acute care crisis-oriented, inpatient, ED, long-term care and other SUD costs.

Research question 3.3a Does the expanded coverage of SUD services change total Medicaid costs?

Research question 3.3b Does the expanded coverage of SUD services change out-of-pocket costs to Medicaid enrollees with an SUD diagnosis?

Research question 3.3c Does the expanded coverage of SUD services increase Medicaid costs on SUD IMD services, SUD pharmacy, outpatient, and rehabilitative costs?

Research question 3.3d Does the expanded coverage of SUD services decrease Medicaid costs on acute care crisis-oriented, inpatient, ED, long-term care and other SUD costs?

Research question 3.3e Does the expanded coverage of SUD services decrease Medicaid spending on non-SUD services for people with an SUD diagnosis?

### **Evaluation Questions**

With the Demonstration goals, hypotheses, and research questions specified, a series of metrics were generated during the Evaluation Proposal Development period. The Evaluation will assess the degree to which the Demonstration was effective in achieving its goals and will examine the processes, facilitators and barriers experienced during the Demonstration period using these metrics.

The sections and tables below detail the quantitative measures to be used to test each hypothesis, the source or custodian of each measure, the sample or population to which the measure is relevant, and the proposed data sources. Measures were generated from the required PHP Quality Metrics, as specified in the RFP for PHPs, Section VII, Attachment E, page 37), the Quality Strategy, the SUD guidance document, and other public sources. Several of these measures will be employed for multiple hypotheses, to examine the effect of different components of the waiver on outcomes or in different Medicaid populations. The data sources and analytic methods are further described below.

### Goal 1: Measurably improve health outcomes via a new delivery system

**Hypothesis 1.1** The implementation of Medicaid managed care will increase access to care, the quality of care, and health outcomes.

Table 1.1: Measures related to Hypothesis 1.1, by Research Question

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Research question those in the target		nplementation of s	tandard plans inc	rease access to	health care for
Getting Care Quickly	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q4 & Q6	Outcome
Getting Needed Care	NQF #: 0006 / AHRQ	Respondents who always desired care or service	Respondents to the CAHPS survey*	CAHPS Q9 & Q18	Outcome

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
	0 !!!				
Use of primary	Quality	Coded as	In PHP	Claims /	Process
care services	Strategy Objective 2.3	receiving primary care	population	Encounter data	
Adolescent Well-	NCQA – HEDIS	Received a well-	Adolescents	Claims /	Process
Care	17168	child visit	age 12-21 in PHP	Encounter data	
Children and	NQF#: 2371 /	Coded as	population Children	Claims /	Process
Adolescents'	NCQA - HEDIS	receiving primary	ages 12	Encounter	110003
Access to Primary	.100/1 112013	care	months – 19	data	
Care Practitioners		34.0	years in PHP	3000	
(4 measures)			population		
(Any) Annual	NQF#: 1388/	Coded as	Beneficiaries	Claims /	Process
Dental Visits	NCQA - HEDIS	receiving 1+	ages 2-20	Encounter	
		outpatient dental	years of age	data	
		visit	with dental		
			coverage		
			included in the		
			PHP contract		
<b>Dental Sealants</b>	NQF#: 2508/	Coded as	Beneficiaries	Claims /	Process
for Children at	NCQA – HEDIS	receiving dental	age 6-9 at	Encounter	
Elevated Caries	/ ADA on	sealants	Elevated	data	
Risk	Behalf of the		Caries Risk in		
	Dental Quality		PHP		
	Alliance		population		
Up to date on	NQF#: 0038 /	Received all	Children who	Claims /	Process
Childhood	NCQA - HEDIS	immunizations	turned age 2	Encounter	
Immunizations		suggested per	in PHP	Data;	
		age	population	Immunization Data	
Immunizations	NQF#: 1407 /	Adolescents age	Medicaid	Claims /	Process
for Adolescents	NCQA - HEDIS	13 who had	enrolled	Encounter	
(2 measures)		specified vaccine	adolescents in	Data;	
		by their 13 <sup>th</sup>	PHP	Immunization	
		birthday	population	Data	

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Customer Service	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q9 & Q18	Outcome
Rating of Health Plan	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q26	Outcome
Rating of all Health Care	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q8	Outcome
Rating of Personal Doctor	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q16	Outcome
Adult BMI Assessment	NQF#: 0023 / NCQA - HEDIS	Coded as having BMI assessment	Beneficiaries 18-74 with an outpatient visit in PHP population	Claims / Encounter Data; PHP data	Process
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents	NQF#: 0024/ NCQA - HEDIS	Coded as having Weight Assessment and Counseling for Nutrition and Physical Activity	Beneficiaries 3-17 in PHP population who had an outpatient visit with a PCP or OB/GYN	Claims / Encounter Data; PHP data	Process
Tobacco Use screening and follow-up	NQF# 2600	Coded as having received tobacco use screening	Adults age 18+ in target population	Claims / Encounter data	Process
Breast Cancer Screening	NQF#: 2372 / NCQA - HEDIS	Coded as receiving breast cancer screening	Women 50-74 years of age in PHP population	Claims / Encounter Data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Cervical Cancer Screening	NQF#: 0032 / NCQA - HEDIS	Coded as receiving cervical cancer screening	Women 21-64 years of age in PHP population	Claims / Encounter Data	Process
Flu vaccine for Adults age 18-64	NQF#: 0039 / NCQA - HEDIS	Coded as receiving Medicaid-paid flu vaccine	Adults age 18- 64 in PHP population	Claims / Encounter Data	Process
Appropriate Testing (for strep) for Children with Pharyngitis	NQF#: 0002 / NCQA - HEDIS	Coded as receiving a strep test	Children age 3-18 in PHP population diagnosed with pharyngitis and dispensed an antibiotic	Claims / Encounter Data	Process
Appropriate Treatment for Children with Upper Respiratory Infection	NQF#: 0069 / NCQA - HEDIS	Coded as receiving appropriate treatment	Children 3 months – 18 years in PHP population given a diagnosis of URI	Claims / Encounter Data	Process
Medication Management for People with Asthma	NQF#: 1799 / NCQA - HEDIS	Coded as receiving medication management	Beneficiaries age 5-64 in PHP population with persistent asthma	Claims / Encounter Data	Process
Asthma Medication Ratio	NQF#: 1800 / NCQA - HEDIS	Medication ratio >=50%	Beneficiaries age 5-64 in PHP population with persistent asthma	Claims / Encounter Data	Process
Avoidance of Antibiotic Treatment in Adults with Acute	NQF#: 0058 / NCQA - HEDIS	Coded as not receiving antibiotics	Adults age 18- 64 in PHP population with a diagnosis of	Claims / Encounter Data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Bronchitis			acute bronchitis		
Annual Monitoring for Patients on Persistent Medications	NQF#: 2371 / NCQA - HEDIS	Coded as receiving 1+ monitoring visit each year	Beneficiaries age 18+ in PHP population who received at least 180 days of outpatient medication for selected conditions	Claims / Encounter Data	Process
Pharmacotherapy Management of COPD Exacerbation (2 measures)	NQF#: 2856 / NCQA - HEDIS	Coded as receiving pharmacotherapy management	Beneficiaries age 40+ in PHP population with an acute inpatient discharge or ED visit	Claims / Encounter Data	Process
Statin Therapy for Patients with Diabetes (2 measures)	NQF#: 0547 / NCQA - HEDIS	Coded as receiving statin therapy	Beneficiaries age 40-75 in PHP population with diabetes and without atherosclerotic cardiovascular disease	Claims / Encounter Data	Process
Statin Therapy for Patients with Cardiovascular Disease (2 measures)	NQF#: 0543 / NCQA - HEDIS	Coded as receiving statin therapy	Men age 21-75 and women age 40-75 in PHP population with atherosclerotic cardiovascular disease	Claims / Encounter Data	Process
Visits in the First 15 Months of Life	NQF#: 1392 / NCQA - HEDIS	Received well- child visits	Children at age 15 months	Claims / Encounter Data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			in PHP population		
Well-Child Visits in the Third, Fourth, Fifth, and Sixth Years of Life+	NQF#: 1516 / NCQA - HEDIS	Received well- child visits	Children age 3-6 in PHP population	Claims / Encounter Data	Process
Concurrent Use of Prescription Opioids and Benzodiazepines	PQA	Received concurrent prescriptions for opioids and benzodiazepines	Adults without a cancer diagnosis and not in hospice in PHP population with two or more prescriptions of opioids with a days supply of over 15 days	Claims / Encounter data	Process
Use of Imaging Studies for Low Back Pain	NQF#: 0052 / NCQA - HEDIS	Coded as receving 1+ imaging procedure	Beneficiaries with a diagnosis of low back pain in PHP population	Claims / Encounter data	Process
Chlamydia Screening in Women	NQF#: 0033 / NCQA - HEDIS	Coded as receiving chlamydia screening	Women 16-24 years of age in PHP population identified as sexually active	Claims / Encounter Data	Process
Screening for pregnancy risk	NC Administrative Measure	Coded as receiving screening for pregnancy risk	Women in PHP population with a viable pregnancy	Claims / Encounter data	Process
Frequency of Prenatal Care (>=81% of expected	NQF#: 1391 / NCQA - HEDIS	Coded as receiving >=81% of expected visits	Women in PHP population with births	Claims / Encounter data; Birth	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
visits)			covered by Medicaid	Certificate Data	
Prenatal and Postpartum Care+	NQF#: 1517 / NCQA - HEDIS	Coded as receiving prenatal and postpartum visits	Women with live births	Claims / Encounter data; Birth Certificate Data	Process
Pregnant smokers screened and treated for tobacco use Research question	NC Modified measure  1.1.c Does the in	Coded as screened and treated	Pregnant tobacco users in PHP population andard plans imp	Birth certificate / Claims / Encounter data brove health out	Process tcomes for
those in the target	t population?	-	•		
All-Cause Hospital Readmission	NQF#: 1768 / NCQA - HEDIS	Readmission within 30 days of discharge	Inpatient hospital stays for beneficiaries age 18+ in PHP population	Claims / Encounter Data	Outcome
30-day hospital readmission rate following hospitalization for SUD		Readmission within 30 days of discharge	Hospital stays in PHP population with a diagnosis of SUD (generally) or OUD (specifically)	Claims / Encounter data	Outcome
Comprehensive Diabetes Care: HbA1c poor control (>9.0) +	NQF#: 0059 / NCQA - HEDIS	Coded as having HbA1c poor control (>9.0)+	Beneficiaries age 18-75 in PHP population with a diabetes diagnosis	Claims / Encounter Data; PHP data	Outcome
Comprehensive Diabetes Care (9 measures)	NQF#: 0061, 0575, 0055 / NCQA - HEDIS	Coded as receiving various measures of	Beneficiaries age 18-75 in PHP	Claims / Encounter	Outcome

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
		comprehensive care	population with a diabetes diagnosis	Data ; PHP data	
Diabetes Short-term Complication Admission Rate	PQI-01, PDI-15	Coded as having an admission for short-term complications	Beneficiaries in PHP population with a diabetes diagnosis	Claims / Encounter data	Outcome
Controlling High Blood Pressure	NQF#: 0018 / NCQA - HEDIS	Coded as having controlled BP	Beneficiaries age 18-85 in PHP population with a diagnosis of HTN	Claims / Encounter Data ; PHP data	Outcome
COPD or Asthma in Older Adult Admissions	PQI-05	Discharges for asthma or COPD	Adult beneficiaries age 40+ in PHP population	Claims / Encounter data	Outcome
Heart Failure Admissions	PQI-08	Discharges for heart failure	Adult beneficiaries in PHP population	Claims / Encounter data	Outcome
Receipt of Preventative Dental Services	NQF#: 1334 / CMS-416	Receipt of a preventative dental service	Beneficiaries ages 1-20 in PHP population enrolled at least 90 days and eligible for EPSDT	Claims / Encounter data	Outcome
Asthma Admissions in Younger Adults	PQI-15	Hospitalized for asthma	Young adult beneficiaries in PHP population	Claims / Encounter data	Outcome

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Gastroenteritis Admissions	PDI-15	Hospitalized for gastroenteritis	Children in PHP population	Claims / Encounter data	Outcome
Urinary Tract Infection Admissions	PDI-18	Hospitalized for UTI	Children in PHP population	Claims / Encounter data	Outcome
Death rate by group (e.g., SUD, SMI)		Died	Adult beneficiaries in PHP population; by key diagnostic group	Claims / Encounter data linked with death certificate data	Outcome
Live Births Weighing Less than 2500 Grams +	NQF#: 1382 / CDC (NC Modification)	Birthweight less than 2500 grams	Live births / live births covered by a PHP since 16 weeks	Birth Certificate / Medicaid eligibility	Outcome
Infant Mortality		Infant death	Live births in PHP population	Birth Certificate / Death Certificate data	Outcome
Healthy Days		Number of self- reported healthy days in month	Medicaid enrollees in PHP population and/or those Based on FPL	BRFSS	Outcome
Tobacco Use Rate (multiple measures)	Public Health Measures	Evidence of tobacco use	Medicaid enrollees in PHP population	BRFSS / CAHPS	Outcome
Overweight / Obesity Rate		Coded as over weight / obese	Medicaid enrollees in PHP population and/or those Based on FPL	BRFSS / CAHPS	Outcome

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Death rate post prison release		Died	Adult beneficiaries in PHP population released from prison	Death Certificate data linked with DOC data and Medicaid enrollment, claims, and encounters	Outcome
those in the target		nplementation of ta	illored plans incre	ease access to n	eaith care for
Getting Care Quickly	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q4 & Q6	Outcome
Getting Needed Care	NQF #: 0006 / AHRQ	Respondents who always desired care or service	Respondents to the CAHPS survey*	CAHPS Q9 & Q18	Outcome
Use of primary care services	Quality Strategy Objective 2.3	Coded as receiving primary care	Enrollees in TP population	Claims / Encounter data	Process
Adolescent Well- Care	NCQA – HEDIS 17168	Received a well- child visit	Adolescents age 12-21 in TP population	Claims / Encounter data	Process
Children and Adolescents' Access to Primary Care Practitioners (4 measures)	NQF#: 2371 / NCQA - HEDIS	Coded as receiving primary care	Children ages 12 months – 19 years in TP population	Claims / Encounter data	Process
(Any) Annual Dental Visits	NQF#: 1388/ NCQA - HEDIS	Coded as receiving 1+ outpatient dental visit	Beneficiaries ages 2-20 years of age in TP population with dental coverage	Claims / Encounter data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			included in the TP contract		
Dental Sealants for Children at Elevated Caries Risk	NQF#: 2508/ NCQA – HEDIS / ADA on Behalf of the Dental Quality Alliance	Coded as receiving dental sealants	Beneficiaries age 6-9 in TP population at elevated caries risk	Claims / Encounter data	Process
Up to date on Childhood Immunizations	NQF#: 0038 / NCQA - HEDIS	Received all immunizations suggested per age	Children who turned age 2 in TP population	Claims / Encounter Data; Immunization Data	Process
Immunizations for Adolescents (2 measures)	NQF#: 1407 / NCQA - HEDIS	Adolescents age 13 who had specified vaccine by their 13 <sup>th</sup> birthday	Medicaid enrolled adolescents in TP population	Claims / Encounter Data; Immunization Data	Process
Research question health care receive		nplementation of B	H I/DD Tailored P	lans improve th	e quality of
Customer Service	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q9 & Q18	Outcome
Rating of Health Plan	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q26	Outcome
Rating of all Health Care	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q8	Outcome
Rating of Personal Doctor	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q16	Outcome

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Adult BMI Assessment	NQF#: 0023 / NCQA - HEDIS	Coded as having BMI assessment	Beneficiaries 18-74 with an outpatient visit in TP population	Claims / Encounter Data; PHP data	Process
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents	NQF#: 0024/ NCQA - HEDIS	Coded as having Weight Assessment and Counseling for Nutrition and Physical Activity	Beneficiaries 3-17 in TP population who had an outpatient visit with a PCP or OB/GYN	Claims / Encounter Data; PHP data	Process
Tobacco Use screening and follow-up Breast Cancer	NQF#: 2372 /	Coded as having received tobacco use screening Coded as	Adults age 18+ in target population Women 50-74	Claims / Encounter data Claims /	Process  Process
Screening	NCQA - HEDIS	receiving breast cancer screening	years of age in TP population	Encounter Data	
Cervical Cancer Screening	NQF#: 0032 / NCQA - HEDIS	Coded as receiving cervical cancer screening	Women 21-64 years of age in TP population	Claims / Encounter Data	Process
Flu vaccine for Adults age 18-64	NQF#: 0039 / NCQA - HEDIS	Coded as receiving Medicaid-paid flu vaccine	Adults age 18- 64 in TP population	Claims / Encounter Data	Process
Appropriate Testing (for strep) for Children with Pharyngitis	NQF#: 0002 / NCQA - HEDIS	Coded as receiving a strep test	Children age 3-18 in TP population diagnosed with pharyngitis and dispensed an antibiotic	Claims / Encounter Data	Process
Appropriate Treatment for Children with Upper Respiratory Infection	NQF#: 0069 / NCQA - HEDIS	Coded as receiving appropriate treatment	Children 3 months – 18 years in TP population given a	Claims / Encounter Data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			diagnosis of URI		
Medication Management for People with Asthma	NQF#: 1799 / NCQA - HEDIS	Coded as receiving medication management	Beneficiaries age 5-64 in TP population with persistent asthma	Claims / Encounter Data	Process
Asthma Medication Ratio	NQF#: 1800 / NCQA - HEDIS	Medication ratio >=50%	Beneficiaries age 5-64 in TP population with persistent asthma	Claims / Encounter Data	Process
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	NQF#: 0058 / NCQA - HEDIS	Coded as not receiving antibiotics	Adults age 18-64 in TP population with a diagnosis of acute bronchitis	Claims / Encounter Data	Process
Annual Monitoring for Patients on Persistent Medications	NQF#: 2371 / NCQA - HEDIS	Coded as receiving 1+ monitoring visit each year	Beneficiaries age 18+ in TP population who received at least 180 days of outpatient medication for selected conditions	Claims / Encounter Data	Process
Pharmacotherapy Management of COPD Exacerbation (2 measures)	NQF#: 2856 / NCQA - HEDIS	Coded as receiving pharmacotherapy management	Beneficiaries age 40+ in TP population with an acute inpatient discharge or ED visit	Claims / Encounter Data	Process
Statin Therapy for Patients with Diabetes (2 measures)	NQF#: 0547 / NCQA - HEDIS	Coded as receiving statin therapy	Beneficiaries age 40-75 in TP population with diabetes	Claims / Encounter Data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			and without atherosclerotic cardiovascular disease		
Statin Therapy for Patients with Cardiovascular Disease (2 measures)	NQF#: 0543 / NCQA - HEDIS	Coded as receiving statin therapy	Men age 21-75 and women age 40-75 in TP population with atherosclerotic cardiovascular disease	Claims / Encounter Data	Process
Well-Child Visits in the Third, Fourth, Fifth, and Sixth Years of Life+	NQF#: 1516 / NCQA - HEDIS	Received well- child visits	Children age 3-6 in PHP population	Claims / Encounter Data	Process
Concurrent Use of Prescription Opioids and Benzodiazepines	PQA	Received concurrent prescriptions for opioids and benzodiazepines	Adults without a cancer diagnosis and not in hospice in TP population with two or more prescriptions of opioids with a days supply of over 15 days	Claims / Encounter data	Process
Use of Imaging Studies for Low Back Pain	NQF#: 0052 / NCQA - HEDIS	Coded as receving 1+ imaging procedure	Beneficiaries with a diagnosis of low back pain in TP population	Claims / Encounter data	Process
Chlamydia Screening in Women	NQF#: 0033 / NCQA - HEDIS	Coded as receiving chlamydia screening	Women 16-24 years of age in TP population	Claims / Encounter Data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			identified as		
Screening for pregnancy risk	NC Administrative Measure	Coded as receiving screening for pregnancy risk	women in TP population with a viable pregnancy	Claims / Encounter data	Process
Frequency of Prenatal Care (>=81% of expected visits)	NQF#: 1391 / NCQA - HEDIS	Coded as receiving >=81% of expected visits	Women in TP population with births covered by Medicaid	Claims / Encounter data; Birth Certificate Data	Process
Prenatal and Postpartum Care+	NQF#: 1517 / NCQA - HEDIS	Coded as receiving prenatal and postpartum visits	Women with live births	Claims / Encounter data; Birth Certificate Data	Process
_		Coded as screened and treated	Pregnant tobacco users in TP population	Birth certificate / Claims / Encounter data lans improve he	Process alth outcomes
All-Cause Hospital Readmission	rget population?  NQF#: 1768 /  NCQA - HEDIS	Readmission within 30 days of discharge	Inpatient hospital stays for beneficiaries age 18+ in TP population	Claims / Encounter Data	Outcome
30-day hospital readmission rate following hospitalization for SUD		Readmission within 30 days of discharge	Hospital stays in TP population with a diagnosis of SUD (generally) or OUD (specifically)	Claims / Encounter data	Outcome

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Comprehensive Diabetes Care: HbA1c poor control (>9.0) +	NQF#: 0059 / NCQA - HEDIS	Coded as having HbA1c poor control (>9.0)+	Beneficiaries age 18-75 in TP population with a diabetes diagnosis	Claims / Encounter Data; PHP data	Outcome
Comprehensive Diabetes Care (9 measures)	NQF#: 0061, 0575, 0055 / NCQA - HEDIS	Coded as receiving various measures of comprehensive care	Beneficiaries age 18-75 in TP population with a diabetes diagnosis	Claims / Encounter Data ; PHP data	Outcome
Diabetes Short-term Complication Admission Rate	PQI-01, PDI-15	Coded as having an admission for short-term complications	Beneficiaries in TP population with a diabetes diagnosis	Claims / Encounter data	Outcome
Controlling High Blood Pressure	NQF#: 0018 / NCQA - HEDIS	Coded as having controlled BP	Beneficiaries age 18-85 in TP population with a diagnosis of HTN	Claims / Encounter Data ; PHP data	Outcome
COPD or Asthma in Older Adult Admissions	PQI-05	Discharges for asthma or COPD	Adult beneficiaries in TP population	Claims / Encounter data	Outcome
Heart Failure Admissions	PQI-08	Discharges for heart failure	Adult beneficiaries in TP population	Claims / Encounter data	Outcome
Receipt of Preventative Dental Services	NQF#: 1334 / CMS-416	Receipt of a preventative dental service	Beneficiaries ages 1-20 in TP population enrolled at least 90 days	Claims / Encounter data	Outcome

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			and eligible for EPSDT		
Asthma Admissions in Younger Adults	PQI-15	Hospitalized for asthma	Young adult beneficiaries in TP population	Claims / Encounter data	Outcome
Gastroenteritis Admissions	PDI-15	Hospitalized for gastroenteritis	Children in TP population	Claims / Encounter data	Outcome
Urinary Tract Infection Admissions	PDI-18	Hospitalized for UTI	Children in TP population	Claims / Encounter data	Outcome
Death rate by group (e.g., SUD, SMI)		Died	Adult beneficiaries in TP population; by key diagnostic group	Claims / Encounter data linked with death certificate data	Outcome
Live Births Weighing Less than 2500 Grams +	NQF#: 1382 / CDC (NC Modification)	Birthweight less than 2500 grams	Live births / live births covered by a TP since 16 weeks	Birth Certificate / Medicaid eligibility	Outcome
Infant Mortality		Infant death	Live births in TP population	Birth Certificate / Death Certificate data	Outcome
Healthy Days		Number of self- reported healthy days in month	Medicaid enrollees in TP population and/or those Based on FPL	BRFSS	Outcome
Tobacco Use Rate (multiple measures)	Public Health Measures	Evidence of tobacco use	Medicaid enrollees in TP population	BRFSS / CAHPS	Outcome
Overweight / Obesity Rate		Coded as over weight / obese	Medicaid enrollees in TP population and/or those	BRFSS / CAHPS	Outcome

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			Based on FPL	_	
Death rate post prison release		Died	Adult beneficiaries in TP population released from prison	Death Certificate data linked with DOC data and Medicaid enrollment, claims, and encounters	Outcome
health care for tho	_	nplementation of spoopulation?	oecialized foster (	care plans increa	ase access to
Getting Care Quickly	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q4 & Q6	Outcome
Getting Needed Care	NQF #: 0006 / AHRQ	Respondents who always desired care or service	Respondents to the CAHPS survey*	CAHPS Q9 & Q18	Outcome
Use of primary care services	Quality Strategy Objective 2.3	Coded as receiving primary care	In SP population	Claims / Encounter data	Process
Adolescent Well- Care	NCQA – HEDIS 17168	Received a well- child visit	Adolescents age 12-21 in SP population	Claims / Encounter data	Process
Children and Adolescents' Access to Primary Care Practitioners (4 measures)	NQF#: 2371 / NCQA - HEDIS	Coded as receiving primary care	Children ages 12 months – 19 years in SP population	Claims / Encounter data	Process
(Any) Annual Dental Visits	NQF#: 1388/ NCQA - HEDIS	Coded as receiving 1+ outpatient dental visit	Beneficiaries ages 2-20 years of age with dental coverage	Claims / Encounter data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			included in the SP contract		
Dental Sealants for Children at Elevated Caries Risk	NQF#: 2508/ NCQA – HEDIS / ADA on Behalf of the Dental Quality Alliance	Coded as receiving dental sealants	Beneficiaries age 6-9 at Elevated Caries Risk in SP population	Claims / Encounter data	Process
Up to date on Childhood Immunizations	NQF#: 0038 / NCQA - HEDIS	Received all immunizations suggested per age	Children who turned age 2 in SP population	Claims / Encounter Data; Immunization Data	Process
Immunizations for Adolescents (2 measures)	NQF#: 1407 / NCQA - HEDIS	Adolescents age 13 who had specified vaccine by their 13 <sup>th</sup> birthday	Medicaid enrolled adolescents in SP population	Claims / Encounter Data; Immunization Data	Process
Research question of health care rece		mplementation of spectors of spectors.	pecialized foster (	care plans impro	ve the quality
Customer Service	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q9 & Q18	Outcome
Rating of Health Plan	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q26	Outcome
Rating of all Health Care	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q8	Outcome
Rating of Personal Doctor	NQF #: 0006 / AHRQ	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q16	Outcome

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Adult BMI Assessment	NQF#: 0023 / NCQA - HEDIS	Coded as having BMI assessment	Beneficiaries 18+ with an outpatient visit in SP population	Claims / Encounter Data; PHP data	Process
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents	NQF#: 0024/ NCQA - HEDIS	Coded as having Weight Assessment and Counseling for Nutrition and Physical Activity	Beneficiaries 3-17 in SP population who had an outpatient visit with a PCP or OB/GYN	Claims / Encounter Data; PHP data	Process
Tobacco Use screening and follow-up	NQF# 2600	Coded as having received tobacco use screening	Adults age 18+ in target population	Claims / Encounter data	Process
Breast Cancer Screening	NQF#: 2372 / NCQA - HEDIS	Coded as receiving breast cancer screening	Women 50-74 years of age in PHP population	Claims / Encounter Data	Process
Cervical Cancer Screening	NQF#: 0032 / NCQA - HEDIS	Coded as receiving cervical cancer screening	Women 21-64 years of age in PHP population	Claims / Encounter Data	Process
Flu vaccine for Adults age 18-64	NQF#: 0039 / NCQA - HEDIS	Coded as receiving Medicaid-paid flu vaccine	Adults age 18- 64 in PHP population	Claims / Encounter Data	Process
Appropriate Testing (for strep) for Children with Pharyngitis	NQF#: 0002 / NCQA - HEDIS	Coded as receiving a strep test	Children age 3-18 in PHP population diagnosed with pharyngitis and dispensed an antibiotic	Claims / Encounter Data	Process
Appropriate Treatment for Children with Upper	NQF#: 0069 / NCQA - HEDIS	Coded as receiving appropriate treatment	Children 3 months – 18 years in PHP population	Claims / Encounter Data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Respiratory Infection			given a diagnosis of URI		
Medication Management for People with Asthma	NQF#: 1799 / NCQA - HEDIS	Coded as receiving medication management	Beneficiaries age 5-64 in PHP population with persistent asthma	Claims / Encounter Data	Process
Asthma Medication Ratio	NQF#: 1800 / NCQA - HEDIS	Medication ratio >=50%	Beneficiaries age 5-64 in PHP population with persistent asthma	Claims / Encounter Data	Process
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	NQF#: 0058 / NCQA - HEDIS	Coded as not receiving antibiotics	Adults age 18- 64 in SP population with a diagnosis of acute bronchitis	Claims / Encounter Data	Process
Annual Monitoring for Patients on Persistent Medications	NQF#: 2371 / NCQA - HEDIS	Coded as receiving 1+ monitoring visit each year	Beneficiaries age 18+ in SP population who received at least 180 days of outpatient medication for selected conditions	Claims / Encounter Data	Process
Visits in the First 15 Months of Life	NQF#: 1392 / NCQA - HEDIS	Received well- child visits	Children at age 15 months in SP population	Claims / Encounter Data	Process
Well-Child Visits in the Third, Fourth,	NQF#: 1516 / NCQA - HEDIS	Received well- child visits	Children age 3-6 in SP population	Claims / Encounter Data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Fifth, and Sixth Years of Life+				_	
Concurrent Use of Prescription Opioids and Benzodiazepines	PQA	Received concurrent prescriptions for opioids and benzodiazepines	Adults without a cancer diagnosis and not in hospice in SP population with two or more prescriptions of opioids with a days supply of over 15 days	Claims / Encounter data	Process
Use of Imaging Studies for Low Back Pain	NQF#: 0052 / NCQA - HEDIS	Coded as receving 1+ imaging procedure	Beneficiaries with a diagnosis of low back pain in SP population	Claims / Encounter data	Process
Chlamydia Screening in Women	NQF#: 0033 / NCQA - HEDIS	Coded as receiving chlamydia screening	Women 16-24 years of age in SP population identified as sexually active	Claims / Encounter Data	Process
Screening for pregnancy risk	NC Administrative Measure	Coded as receiving screening for pregnancy risk	Women in SP population with a viable pregnancy	Claims / Encounter data	Process
Frequency of Prenatal Care (>=81% of expected visits)	NQF#: 1391 / NCQA - HEDIS	Coded as receiving >=81% of expected visits	Women in SP population with births covered by Medicaid	Claims / Encounter data; Birth Certificate Data	Process
Prenatal and Postpartum Care+	NQF#: 1517 / NCQA - HEDIS	Coded as receiving prenatal and postpartum visits	Women with live births	Claims / Encounter data; Birth Certificate Data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Pregnant smokers screened and treated for tobacco use	NC Modified measure	Coded as screened and treated	Pregnant tobacco users in PHP population	Birth certificate / Claims / Encounter data	Process
Research question 1.1.i Does the implementation of specialized foster care plans improve health outcomes for those in the target population?					
All-Cause Hospital Readmission	e in the target po NQF#: 1768 / NCQA - HEDIS	Readmission within 30 days of discharge	Inpatient hospital stays for beneficiaries age 18+ in SP population	Claims / Encounter Data	Outcome
30-day hospital readmission rate following hospitalization for SUD		Readmission within 30 days of discharge	Hospital stays in SP population with a diagnosis of SUD (generally) or OUD (specifically)	Claims / Encounter data	Outcome
Comprehensive Diabetes Care: HbA1c poor control (>9.0) +	NQF#: 0059 / NCQA - HEDIS	Coded as having HbA1c poor control (>9.0)+	Beneficiaries age 18-75 in SP population with a diabetes diagnosis	Claims / Encounter Data; PHP data	Outcome
Comprehensive Diabetes Care (9 measures)	NQF#: 0061, 0575, 0055 / NCQA - HEDIS	Coded as receiving various measures of comprehensive care	Beneficiaries age 18+ in SP population with a diabetes diagnosis	Claims / Encounter Data ; PHP data	Outcome
Diabetes Short-term Complication Admission Rate	PQI-01, PDI-15	Coded as having an admission for short-term complications	Beneficiaries in SP population with a	Claims / Encounter data	Outcome

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			diabetes diagnosis		
Controlling High Blood Pressure	NQF#: 0018 / NCQA - HEDIS	Coded as having controlled BP	Beneficiaries age 18+ in SP population with a diagnosis of HTN	Claims / Encounter Data ; PHP data	Outcome
COPD or Asthma in Older Adult Admissions	PQI-05	Discharges for asthma or COPD	Adult beneficiaries in SP population	Claims / Encounter data	Outcome
Heart Failure Admissions	PQI-08	Discharges for heart failure	Adult beneficiaries in SP population	Claims / Encounter data	Outcome
Receipt of Preventative Dental Services	NQF#: 1334 / CMS-416	Receipt of a preventative dental service	Beneficiaries ages 1-20 in SP population enrolled at least 90 days and eligible for EPSDT	Claims / Encounter data	Outcome
Asthma Admissions in Younger Adults	PQI-15	Hospitalized for asthma	Young adult beneficiaries in SP population	Claims / Encounter data	Outcome
Gastroenteritis Admissions	PDI-15	Hospitalized for gastroenteritis	Children in SP population	Claims / Encounter data	Outcome
Urinary Tract Infection Admissions	PDI-18	Hospitalized for UTI	Children in SP population	Claims / Encounter data	Outcome
Death rate by group (e.g., SUD, SMI)		Died	Adult beneficiaries in SP population; by	Claims / Encounter data linked with death	Outcome

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			key diagnostic group	certificate data	
Live Births Weighing Less than 2500 Grams +	NQF#: 1382 / CDC (NC Modification)	Birthweight less than 2500 grams	Live births / live births covered by a SP since 16 weeks	Birth Certificate / Medicaid eligibility	Outcome
Infant Mortality		Infant death	Live births in SP population	Birth Certificate / Death Certificate data	Outcome
Death rate post prison release		Died	Adult beneficiaries in SP population released from prison	Death Certificate data linked with DOC data and Medicaid enrollment, claims, and encounters	Outcome

<sup>\*</sup> Claims / Encounter data refers to fee-for-service (FFS) claims data prior to Nov 1, 2021 as well as remaining populations or services subject to FFS payments after Nov 1, 2021; LME/MCO encounter data; PHP encounter data; and State Operated Facilities (IMD) utilization data. + priority measures are those measures which PHPs are required to monitor in the Quality Strategy and may be used for an annual disparity report and may be published annually on DHHS's website.

**Hypothesis 1.2**: The implementation of Medicaid managed care will increase the rate of use of behavioral health services at the appropriate level of care and improve the quality of behavioral health care received.

Table 1.2: Measures related to Hypothesis 1.2, by Research Question

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
_		e implementation of	=		
Antidepressant	NQF#:	appropriate level of Beneficiaries who	Beneficiaries	Claims /	Process
Medication	0105/	remained on	age 18 and older	Encounter	Process
Management (two	NCQA -	antidepressant	who filled at	Data	
measures)	HEDIS	treatment	least one	Data	
measures,	112313	a cutilicité	prescription for antidepressant medication		
Depression	NQMC:	Evidence of	Beneficiaries	Claims /	Process
screening among	004006	depression	with SUD	Encounter	<del>-</del>
those with SUD		screening		data	
Follow-up After	NQF#:	Evidence of	Beneficiaries	Claims /	Process
Hospitalization for	0576/	outpatient visit in	age 6+ who	Encounter	
Mental Illness or	NCQA -	the appropriate	were	data	
Alcohol / Other	HEDIS	time frame	hospitalized for		
Drug Treatment+			treatment of		
(7/30 days)			selected mental illnesses		
Follow-up for	NQF#:	Evidence of	Children newly	Claims /	Process
Children	0108/	outpatient visit in	prescribed	Encounter	
Prescribed ADHD	NCQA -	the appropriate	ADHD	data	
Medication (2 measures)	HEDIS	time frame	medications		
Initiation and	NQF#:	Initiation of SUD	Adolescent and	Claims /	Process
Engagement of	0004/	treatment	adult	Encounter	
SUD Treatment+	NCQA -		beneficiaries	data	
	HEDIS		with a new		
Banding La	NOF"	e di	episode of SUD	Clatter /	D
Medical Assistance	NQF#:	Evidence of receipt	Adults who are	Claims /	Process
with Smoking and	0027/	of advice or	current tobacco	Encounters;	
Tobacco Use Cessation	NCQA - HEDIS	treatments to quit	users	PHP data; CAHPS	
CESSALIUII	חבטוט			САПРЭ	
Continuity of	NQF#:	MAT use of 180+	Those with a	Claims /	Process
Pharmacotherapy with OUD	3175	days	diagnosis of OUD and MAT	Encounter data	

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Concurrent Use of Prescription Opioids and Benzodiazepines	PQA	Contemporaneous use of opioids and benzodiazepines	Adults without a cancer diagnosis and not in hospice with two or more prescriptions of opioids with a supply of over 15 days	Claims / Encounter data	Process
ED visits for SUD- related diagnoses and specifically for OUD (2 measures)	NQF: 2605	Evidence of 1+ ED visits for SUD	Children age 12 and over and adults with SUD	Claims / Encounter data	Process
IP visits for SUD and specifically for OUD		Evidence of 1+ IP visits for SUD	Children age 12 and over and adults with SUD	Claims / Encounter data	Process
· ·		e implementation of the target populatio	-	prove the quality	y of behavioral
Antidepressant Medication Management (two measures)	NQF#: 0105/ NCQA - HEDIS	Beneficiaries who remained on antidepressant treatment	Beneficiaries age 18 and older who filled at least one prescription for antidepressant medication	Claims / Encounter Data	Process
Depression screening among those with SUD	NQMC: 004006	Evidence of depression screening	Beneficiaries with SUD	Claims / Encounter data	Process
Follow-up After Hospitalization for Mental Illness or Alcohol / Other Drug Treatment+ (7/30 days)	NQF#: 0576/ NCQA - HEDIS	Evidence of outpatient visit in the appropriate time frame	Beneficiaries age 6+ who were hospitalized for treatment of selected mental illnesses	Claims / Encounter data	Process
Follow-up for Children Prescribed ADHD Medication (2 measures)	NQF#: 0108/ NCQA - HEDIS	Evidence of outpatient visit in the appropriate time frame	Children newly prescribed ADHD medications	Claims / Encounter data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Medical Assistance with Smoking and Tobacco Use Cessation	NQF#: 0027/ NCQA - HEDIS	Evidence of receipt of advice or treatments to quit	Adults who are current tobacco users	Claims / Encounters; PHP data; CAHPS	Process
Continuity of Pharmacotherapy with OUD	NQF#: 3175	MAT use of 180+ days	Those with a diagnosis of OUD and MAT	Claims / Encounter data	Process
Concurrent Use of Prescription Opioids and Benzodiazepines	PQA	Contemporaneous use of opioids and benzodiazepines	Adults without a cancer diagnosis and not in hospice with two or more prescriptions of opioids with a supply of over 15 days	Claims / Encounter data	Process
ED visits for SUD- related diagnoses and specifically for OUD (2 measures)	NQF: 2605	Evidence of 1+ ED visits for SUD	Children age 12 and over and adults with SUD	Claims / Encounter data	Process
IP visits for SUD and specifically for OUD		Evidence of 1+ IP visits for SUD	Children age 12 and over and adults with SUD	Claims / Encounter data	Process
		e implementation of I e appropriate level of			
Adherence to Antipsychotic Medications for Individuals with Schizophrenia	NQF# 1879 NCQA - HEDIS	PDC >=80% and at least two Rx claims	Adults with an administrative diagnosis of Schizophrenia; during time periods not hospitalized	Claims / Encounter data*	Process
Antidepressant Medication Management (two measures)	NQF#: 0105/ NCQA - HEDIS	Beneficiaries who remained on antidepressant treatment	Beneficiaries age 18 and older who filled at least one prescription for antidepressant medication	Claims / Encounter Data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Use of behavioral health care for people with SMI or SUD		Evidence of behavioral health care use	Children, Adults in target population	Claims / Encounter data	Process
Depression screening among those with SUD	NQMC: 004006	Evidence of depression screening	Beneficiaries with SUD	Claims / Encounter data	Process
Follow-up After Hospitalization for Mental Illness or Alcohol / Other Drug Treatment+ (7/30 days)	NQF#: 0576/ NCQA - HEDIS	Evidence of outpatient visit in the appropriate time frame	Beneficiaries age 6+ who were hospitalized for treatment of selected mental illnesses	Claims / Encounter data	Process
Follow-up for Children Prescribed ADHD Medication (2 measures)	NQF#: 0108/ NCQA - HEDIS	Evidence of outpatient visit in the appropriate time frame	Children newly prescribed ADHD medications	Claims / Encounter data	Process
Initiation and Engagement of SUD Treatment+	NQF#: 0004/ NCQA - HEDIS	Initiation of SUD treatment	Adolescent and adult beneficiaries with a new episode of SUD	Claims / Encounter data	Process
Medical Assistance with Smoking and Tobacco Use Cessation	NQF#: 0027/ NCQA - HEDIS	Evidence of receipt of advice or treatments to quit	Adults who are current tobacco users	Claims / Encounters; PHP data; CAHPS	Process
Continuity of Pharmacotherapy with OUD	NQF#: 3175	MAT use of 180+ days	Those with a diagnosis of OUD and MAT	Claims / Encounter data	Process
Concurrent Use of Prescription Opioids and Benzodiazepines	PQA	Contemporaneous use of opioids and benzodiazepines	Adults without a cancer diagnosis and not in hospice with two or more prescriptions of opioids with a	Claims / Encounter data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			supply of over 15 days		
ED visits for SUD- related diagnoses and specifically for OUD (2 measures)	NQF: 2605	Evidence of 1+ ED visits for SUD	Children age 12 and over and adults with SUD	Claims / Encounter data	Process
IP visits for SUD and specifically for OUD		Evidence of 1+ IP visits for SUD	Children age 12 and over and adults with SUD	Claims / Encounter data	Process
		e implementation of for those in the targe		lans improve th	e quality of
Adherence to Antipsychotic Medications for Individuals with Schizophrenia	NQF# 1879 NCQA - HEDIS	PDC >=80% and at least two Rx claims	Adults with an administrative diagnosis of Schizophrenia; during time periods not hospitalized	Claims / Encounter data*	Process
Antidepressant Medication Management (two measures)	NQF#: 0105/ NCQA - HEDIS	Beneficiaries who remained on antidepressant treatment	Beneficiaries age 18 and older who filled at least one prescription for antidepressant medication	Claims / Encounter Data	Process
Depression screening among those with SUD	NQMC: 004006	Evidence of depression screening	Beneficiaries with SUD	Claims / Encounter data	Process
Follow-up After Hospitalization for Mental Illness or Alcohol / Other Drug Treatment+ (7/30 days)	NQF#: 0576/ NCQA - HEDIS	Evidence of outpatient visit in the appropriate time frame	Beneficiaries age 6+ who were hospitalized for treatment of selected mental illnesses	Claims / Encounter data	Process
Follow-up for Children Prescribed ADHD Medication (2 measures)	NQF#: 0108/ NCQA - HEDIS	Evidence of outpatient visit in the appropriate time frame	Children newly prescribed ADHD medications	Claims / Encounter data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Medical Assistance with Smoking and Tobacco Use Cessation	NQF#: 0027/ NCQA - HEDIS	Evidence of receipt of advice or treatments to quit	Adults who are current tobacco users	Claims / Encounters; PHP data; CAHPS	Process
Continuity of Pharmacotherapy with OUD	NQF#: 3175	MAT use of 180+ days	Those with a diagnosis of OUD and MAT	Claims / Encounter data	Process
Concurrent Use of Prescription Opioids and Benzodiazepines	PQA	Contemporaneous use of opioids and benzodiazepines	Adults without a cancer diagnosis and not in hospice with two or more prescriptions of opioids with a supply of over 15 days	Claims / Encounter data	Process
ED visits for SUD- related diagnoses and specifically for OUD (2 measures)	NQF: 2605	Evidence of 1+ ED visits for SUD	Children age 12 and over and adults with SUD	Claims / Encounter data	Process
IP visits for SUD and specifically for OUD		Evidence of 1+ IP visits for SUD	Children age 12 and over and adults with SUD	Claims / Encounter data	Process
		e implementation of at the appropriate le	-	-	
Adherence to Antipsychotic Medications for Individuals with Schizophrenia	NQF# 1879 NCQA - HEDIS	PDC >=80% and at least two Rx claims	Adults with an administrative diagnosis of Schizophrenia; during time periods not hospitalized	Claims / Encounter data*	Process
Antidepressant Medication Management (two measures)	NQF#: 0105/ NCQA - HEDIS	Beneficiaries who remained on antidepressant treatment	Beneficiaries age 18 and older who filled at least one prescription for antidepressant medication	Claims / Encounter Data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Use of behavioral health care for people with SMI or SUD		Evidence of behavioral health care use	Children, Adults in target population	Claims / Encounter data	Process
Depression screening among those with SUD	NQMC: 004006	Evidence of depression screening	Beneficiaries with SUD	Claims / Encounter data	Process
Follow-up After Hospitalization for Mental Illness or Alcohol / Other Drug Treatment+ (7/30 days)	NQF#: 0576/ NCQA - HEDIS	Evidence of outpatient visit in the appropriate time frame	Beneficiaries age 6+ who were hospitalized for treatment of selected mental illnesses	Claims / Encounter data	Process
Follow-up for Children Prescribed ADHD Medication (2 measures)	NQF#: 0108/ NCQA - HEDIS	Evidence of outpatient visit in the appropriate time frame	Children newly prescribed ADHD medications	Claims / Encounter data	Process
Initiation and Engagement of SUD Treatment+	NQF#: 0004/ NCQA - HEDIS	Initiation of SUD treatment	Adolescent and adult beneficiaries with a new episode of SUD	Claims / Encounter data	Process
Medical Assistance with Smoking and Tobacco Use Cessation	NQF#: 0027/ NCQA - HEDIS	Evidence of receipt of advice or treatments to quit	Adults who are current tobacco users	Claims / Encounters; PHP data; CAHPS	Process
Continuity of Pharmacotherapy with OUD	NQF#: 3175	MAT use of 180+ days	Those with a diagnosis of OUD and MAT	Claims / Encounter data	Process
Concurrent Use of Prescription Opioids and Benzodiazepines	PQA	Contemporaneous use of opioids and benzodiazepines	Adults without a cancer diagnosis and not in hospice with two or more prescriptions of opioids with a	Claims / Encounter data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			supply of over 15 days		
ED visits for SUD- related diagnoses and specifically for OUD (2 measures)	NQF: 2605	Evidence of 1+ ED visits for SUD	Children age 12 and over and adults with SUD	Claims / Encounter data	Process
IP visits for SUD and specifically for OUD		Evidence of 1+ IP visits for SUD	Children age 12 and over and adults with SUD	Claims / Encounter data	Process
		e implementation of s ed for those in the tar	-	are plans impro	ve the quality
Adherence to Antipsychotic Medications for Individuals with Schizophrenia	NQF# 1879 NCQA - HEDIS	PDC >=80% and at least two Rx claims	Adults with an administrative diagnosis of Schizophrenia; during time periods not hospitalized	Claims / Encounter data*	Process
Antidepressant Medication Management (two measures)	NQF#: 0105/ NCQA - HEDIS	Beneficiaries who remained on antidepressant treatment	Beneficiaries age 18 and older who filled at least one prescription for antidepressant medication	Claims / Encounter Data	Process
Depression screening among those with SUD	NQMC: 004006	Evidence of depression screening	Beneficiaries with SUD	Claims / Encounter data	Process
Follow-up After Hospitalization for Mental Illness or Alcohol / Other Drug Treatment+ (7/30 days)	NQF#: 0576/ NCQA - HEDIS	Evidence of outpatient visit in the appropriate time frame	Beneficiaries age 6+ who were hospitalized for treatment of selected mental illnesses	Claims / Encounter data	Process
Follow-up for Children Prescribed ADHD Medication (2 measures)	NQF#: 0108/ NCQA - HEDIS	Evidence of outpatient visit in the appropriate time frame	Children newly prescribed ADHD medications	Claims / Encounter data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Medical Assistance with Smoking and Tobacco Use Cessation	NQF#: 0027/ NCQA - HEDIS	Evidence of receipt of advice or treatments to quit	Adults who are current tobacco users	Claims / Encounters; PHP data; CAHPS	Process
Continuity of Pharmacotherapy with OUD	NQF#: 3175	MAT use of 180+ days	Those with a diagnosis of OUD and MAT	Claims / Encounter data	Process
Concurrent Use of Prescription Opioids and Benzodiazepines	PQA	Contemporaneous use of opioids and benzodiazepines	Adults without a cancer diagnosis and not in hospice with two or more prescriptions of opioids with a supply of over 15 days	Claims / Encounter data	Process
ED visits for SUD- related diagnoses and specifically for OUD (2 measures)	NQF: 2605	Evidence of 1+ ED visits for SUD	Children age 12 and over and adults with SUD	Claims / Encounter data	Process
IP visits for SUD and specifically for OUD		Evidence of 1+ IP visits for SUD	Children age 12 and over and adults with SUD	Claims / Encounter data	Process

<sup>\*</sup> Claims / Encounter data refers to fee-for-service (FFS) claims data prior to Nov 1, 2021 as well as remaining populations or services subject to FFS payments after Nov 1, 2021; LME/MCO encounter data; PHP encounter data; and State Operated Facilities (IMD) utilization data. + priority measures are those measures which PHPs are required to monitor in the Quality Strategy and may be used for an annual disparity report and may be published annually on DHHS's website.

**Hypothesis 1.3**: The implementation of Medicaid managed care will increase the use of Medication-assisted treatment (MAT) and other opioid treatment services and decrease the long-term use of opioids.

Table 1.3: Measures related to Hypothesis 1.3, by Research Question

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome					
Research question 1.3.a Does the implementation of standard plans increase the use of MAT for those in the target population?										
Use of pharmacotherapy for opioid use disorder (OUD)	NQF 3400	Use of MAT	Beneficiaries with OUD	Claims / Encounters	Outcome					
Number of providers with DEA DATA 2000 waivers			NC licensed providers	NC Licensure data / DEA DATA 2000 waiver data	Process					
Number of providers with DEA DATA 2000 waivers who have written prescriptions for Medicaid enrollees for MAT			NC licensed providers with DEA waivers	CSRS / Medicaid claims	Process					
Research question 1 medication opioid to		-	•		se of non-					
Percent of SUD diagnosed beneficiaries who receive an SUD treatment service		Evidence of psychosocial service for SUD	Adults with a current diagnosis of SUD	Claims / Encounters	Outcome					
Research question 1		mplementation	of standard plans	decrease the p	robability of long-					
Long-Term Use of Opioids	i	TBD	Beneficiaries with opioid use	Claims / Encounters	Outcome					
Use of Opioids at High Dosage in Persons without Cancer	NQF#:2940/ PQA	Evidence of opioid use of greater than 120mg for 90 consecutive days or longer	Adults without Cancer, with two or more prescription claims for opioids filled on at least two separate days, for which the sum of the days	Claims / Encounter data	Outcome					

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			supply is greater than or equal to 15.		
Use of Opioids from Multiple Providers in Persons Without Cancer	NQF#:2950/ PQA	Evidence of opioid prescription claims from 4 or more prescribers AND 4 or more pharmacies	Adults without Cancer, with two or more prescription claims for opioids filled on at least two separate days, for which the sum of the days supply is greater than or equal to 15.	Claims / Encounter data	Outcome
Reduced incarceration for drug-related charges			Adults with SUD	DOC data	Outcome
Research question 1 for those in the target		-	of BH I/DD Tailor	ed Plans increas	se the use of MAT
Use of pharmacotherapy for opioid use disorder (OUD)	NQF 3400	Use of MAT	Beneficiaries with OUD	Claims / Encounters	Outcome
Number of providers with DEA DATA 2000 waivers			NC licensed providers	NC Licensure data / DEA DATA 2000 waiver data	Process
Number of providers with DEA DATA 2000 waivers who have written prescriptions for Medicaid enrollees for MAT			NC licensed providers with DEA waivers	CSRS / Medicaid claims	Process

Measure	Measure	Numerator	Denominator	Data	Process /
	custodian			Sources	Outcome
Research question 1	3.e Does the i	mplementation	of BH I/DD Tailor	ed Plans increa	se the use of non-
medication opioid t	reatment servi	ces for those in	the target populat	tion?	
Percent of SUD		Evidence of	Adults with a	Claims /	Outcome
diagnosed		psychosocial	current	Encounters	
beneficiaries who		service for	diagnosis of		
receive an SUD		SUD	SUD		
treatment service					
Research question 1		mplementation	of BH I/DD Tailore	ed Plans decrea	se the probability
of long-term use of	opioids?				
Long-Term Use of		TBD	Beneficiaries	Claims /	Outcome
Opioids			with opioid use	Encounters	
Use of Opioids at	NQF#:2940/	Evidence of	Adults without	Claims /	Outcome
High Dosage in	PQA	opioid use of	Cancer, with	Encounter	
Persons without		greater than	two or more	data	
Cancer		120mg for 90	prescription		
		consecutive	claims for		
		days or	opioids filled on		
		longer	at least two		
			separate days,		
			for which the		
			sum of the days		
			supply is		
			greater than or		
			equal to 15.		
Use of Opioids	NQF#:2950/	Evidence of	Adults without	Claims /	Outcome
from Multiple	PQA	opioid	Cancer, with	Encounter	
Providers in		prescription	two or more	data	
Persons Without		claims from 4	prescription		
Cancer		or more	claims for		
		prescribers	opioids filled on		
		AND 4 or	at least two		
		more	separate days,		
		pharmacies	for which the		
			sum of the days		
			supply is		
			greater than or		
			equal to 15.		
Reduced			Adults with	DOC data	Outcome
incarceration for			SUD		

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
drug-related charges					
Research question 1	1.3.g Does the i	mplementation	of specialized fos	ter care plans i	ncrease the use of
MAT for those in th	e target popula	ntion?			
Use of	NQF 3400	Use of MAT	Beneficiaries	Claims /	Outcome
pharmacotherapy			with OUD	Encounters	
for opioid use					
disorder (OUD)					
Research question 1	L.3.h Does the i	implementation	of specialized fos	ter care plans i	ncrease the use of
non-medication opi	oid treatment	services for thos	se in the target po	pulation?	
Percent of SUD		Evidence of	Adults with a	Claims /	Outcome
diagnosed		psychosocial	current	Encounters	
beneficiaries who		service for	diagnosis of		
receive an SUD		SUD	SUD		
treatment service					
Research question 1	3.i Does the i	mplementation	of specialized fost	er care plans d	ecrease the
probability of long-	erm use of opi	oids?			
Long-Term Use of		TBD	Beneficiaries	Claims /	Outcome
Opioids			with opioid use	Encounters	
Use of Opioids at	NQF#:2940/	Evidence of	Adults without	Claims /	Outcome
High Dosage in	PQA	opioid use of	Cancer, with	Encounter	
Persons without		greater than	two or more	data	
Cancer		120mg for 90	prescription		
		consecutive	claims for		
		days or	opioids filled on		
		longer	at least two		
			separate days,		
			for which the		
			sum of the days		
			supply is		
			greater than or		
			equal to 15.		
Use of Opioids	NQF#:2950/	Evidence of	Adults without	Claims /	Outcome
from Multiple	PQA	opioid	Cancer, with	Encounter	
Providers in		prescription	two or more	data	
<b>Persons Without</b>		claims from 4	prescription		
Cancer		or more	claims for		
		prescribers	opioids filled on		
		AND 4 or	at least two		
			separate days,		

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
		more pharmacies	for which the sum of the days supply is greater than or equal to 15.		
Reduced incarceration for drug-related charges			Adults with SUD	DOC data	Outcome

<sup>\*</sup> Claims / Encounter data refers to fee-for-service (FFS) claims data prior to Nov 1, 2021 as well as remaining populations or services subject to FFS payments after Nov 1, 2021; LME/MCO encounter data; PHP encounter data; and State Operated Facilities (IMD) utilization data. + priority measures are those measures which PHPs are required to monitor in the Quality Strategy and may be used for an annual disparity report and may be published annually on DHHS's website. CSRS refers to data from the Controlled Substances Reporting System.

**Hypothesis 1.4**: Implementation of Advanced Medical Homes will increase the delivery of care management services and will improve quality of care and health outcomes.

Table 1.4: Measures related to Hypothesis 1.4, by Research Question

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Research question	on 1.4.a Doe	s the implement	ation of AMHs an	d HHs increase	the probability of
receiving care m	anagement	services?			
Number / % of		AMH Tier 3	Providers	PHP Network	Process
practices on		providers		data	
the					
PHP panel that					
attest to being					
a level 3 AMH					
Number of	Quality	Enrollees	All	Claims and	Process
enrollees	Strategy	attributed to		Encounters	
attributed to	Objective	an AMH			
an Advanced	2.2				
Medical Home					
Number of		Evidence of	All	Care	Outcome
		care		management	
				databases	

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
enrollees receiving care management		management receipt			
Research question received?	on 1.4.b Doe	s the implement	ation of AMHs an	d HHs improve	the quality of care
Flu vaccine for Adults age 18- 64	NQF#: 0039 / NCQA - HEDIS	Coded as receiving Medicaid-paid flu vaccine	Adults age 18- 64 in PHP population	Claims / Encounter Data	Process
Medication Management for People with Asthma	NQF#: 1799 / NCQA - HEDIS	Coded as receiving medication management	Beneficiaries age 5-64 in PHP population with persistent asthma	Claims / Encounter Data	Process
Asthma Medication Ratio	NQF#: 1800 / NCQA - HEDIS	Medication ratio >=50%	Beneficiaries age 5-64 in PHP population with persistent asthma	Claims / Encounter Data	Process
Antidepressant Medication Management (two measures)	NQF#: 0105/ NCQA - HEDIS	Beneficiaries who remained on antidepressant treatment	Beneficiaries age 18 and older who filled at least one prescription for antidepressant medication	Claims / Encounter Data	Process
Medical Assistance with Smoking and Tobacco Use Cessation	NQF#: 0027/ NCQA - HEDIS	Evidence of receipt of advice or treatments to quit	Adults who are current tobacco users	Claims / Encounters; PHP data; CAHPS	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Follow-up After Hospitalization for Mental Illness or Alcohol / Other Drug Treatment+ (7/30 days)	NQF#: 0576/ NCQA - HEDIS	Evidence of outpatient visit in the appropriate time frame	Beneficiaries age 6+ who were hospitalized for treatment of selected mental illnesses	Claims / Encounter data	Process
Follow-up for Children Prescribed ADHD Medication (2 measures)	NQF#: 0108/ NCQA - HEDIS	Evidence of outpatient visit in the appropriate time frame	Children newly prescribed ADHD medications	Claims / Encounter data	Process
Well-Child Visits in the Third, Fourth, Fifth, and Sixth Years of Life+	NQF#: 1516 / NCQA - HEDIS	Received well- child visits	Children age 3-6 in PHP population	Claims / Encounter Data	Process
Up to date on Childhood Immunizations	NQF#: 0038 / NCQA - HEDIS	Received all immunizations suggested per age	Children who turned age 2 year	Claims / Encounter Data; Immunization Data	Process
Immunizations for Adolescents (2 measures)	NQF#: 1407 / NCQA - HEDIS	Adolescents age 13 who had specified vaccine by their 13 <sup>th</sup> birthday	Medicaid enrolled adolescents	Claims / Encounter Data; Immunization Data	Process
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents	NQF#: 0024/ NCQA - HEDIS	Coded as having Weight Assessment and Counseling for Nutrition and Physical Activity	Beneficiaries 3-17 in PHP population who had an outpatient visit with a PCP or OB/GYN	Claims / Encounter Data; PHP data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Cervical Cancer Screening	NQF#: 0032 / NCQA - HEDIS	Coded as receiving cervical cancer screening	Women 21-64 years of age in PHP population	Claims / Encounter Data	Process
Comprehensive Diabetes Care: HbA1c poor control (>9.0) +	NQF#: 0059 / NCQA - HEDIS	Coded as having HbA1c poor control (>9.0)+	Beneficiaries age 18-75 in PHP population with a diabetes diagnosis	Claims / Encounter Data; PHP data	Outcome
Research question	on 1.4.c Doe	s the implementa		d HHs improve	health outcomes?
All-Cause Hospital Readmission	NQF#: 1768 / NCQA - HEDIS	Readmission within 30 days of discharge	Inpatient hospital stays for beneficiaries age 18+ in PHP population	Claims / Encounter Data	Outcome
Controlling High Blood Pressure	NQF#: 0018 / NCQA - HEDIS	Coded as having controlled BP	Beneficiaries age 18-85 in PHP population with a diagnosis of HTN	Claims / Encounter Data ; PHP data	Outcome
Diabetes Short-term Complication Admission Rate	PQI-01, PDI-15	Coded as having an admission for short-term complications	Beneficiaries in PHP population with a diabetes diagnosis	Claims / Encounter data	Outcome
COPD or Asthma in Older Adult Admissions	PQI-05	Discharges for asthma or COPD	Adult beneficiaries age 40+ in PHP population	Claims / Encounter data	Outcome
Heart Failure Admissions	PQI-08	Discharges for heart failure	Adult beneficiaries	Claims / Encounter data	Outcome

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
			in PHP population		
Asthma Admissions in Younger Adults	PQI-15	Hospitalized for asthma	Young adult beneficiaries in PHP population	Claims / Encounter data	Outcome
Gastroenteritis Admissions	PDI-15	Hospitalized for gastroenteritis	Children in PHP population	Claims / Encounter data	Outcome
Urinary Tract Infection Admissions	PDI-18	Hospitalized for UTI	Children in PHP population	Claims / Encounter data	Outcome

**Hypothesis 1.5**: The implementation of Medicaid managed care will reduce disparities in the quality of care received.

Table 1.5: Measures related to Hypothesis 1.5, by Research Question

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
•	•		ndard plans increase eq	uity in the q	uality of
care for those in the	target populatio	n?			
Appropriate	NQF#: 0069 /	Coded as	Children 3 months –	Claims /	Process
Treatment for	NCQA - HEDIS	receiving	18 years in PHP	Encounter	
Children with		appropriate	population given a	Data	
<b>Upper Respiratory</b>		treatment	diagnosis of URI		
Infection					
<b>Dental Sealants</b>	NQF#: 2508/	Coded as	Beneficiaries age 6-9	Claims /	Process
for Children at	NCQA – HEDIS	receiving dental	at Elevated Caries	Encounter	
<b>Elevated Caries</b>	/ ADA on	sealants	Risk in PHP	data	
Risk	Behalf of the		population		
	<b>Dental Quality</b>				
	Alliance				
Flu vaccine for	NQF#: 0039 /	Coded as	Adults age 18-64 in	Claims /	Process
Adults age 18-64	NCQA - HEDIS	receiving	PHP population	Encounter	
		Medicaid-paid flu		Data	
		vaccine			

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
· ·	-		I/DD Tailored Plans inc	rease equity	in the
quality of care for the		• •			
Follow-up for	NQF#: 0108/	Evidence of	Children newly	Claims /	Process
Children Prescribed	NCQA - HEDIS	outpatient visit in	prescribed ADHD	Encounter	
ADHD Medication		the appropriate	medications	data	
(2 measures)		time frame			
Initiation and	NQF#: 0004/	Initiation of SUD	Adolescent and	Claims /	Process
Engagement of	NCQA - HEDIS	treatment	adult beneficiaries	Encounter	
SUD Treatment+			with a new episode of SUD	data	
Adherence to	NQF# 1879	PDC >=80% and	Adults with an	Claims /	Process
Antipsychotic	NCQA - HEDIS	at least two Rx	administrative	Encounter	
Medications for		claims	diagnosis of	data*	
Individuals with			Schizophrenia;		
Schizophrenia			during time periods		
			not hospitalized		
Research question 1.	5.c Does the imp	lementation of spec	cialized foster care plan	ns increase e	quity in
the quality of care fo	r those in the ta	rget population?			
Follow-up for	NQF#: 0108/	Evidence of	Children newly	Claims /	Process
Children Prescribed	NCQA - HEDIS	outpatient visit in	prescribed ADHD	Encounter	
ADHD Medication		the appropriate	medications	data	
(2 measures)		time frame			
Antidepressant	NQF#: 0105/	Beneficiaries who	Beneficiaries age 18	Claims /	Process
Medication	NCQA - HEDIS	remained on	and older who filled	Encounter	
Management (two		antidepressant	at least one	Data	
measures)		treatment	prescription for		
			antidepressant		
			medication		

**Hypothesis 2.1**: The implementation of Medicaid managed care will decrease the use of emergency departments for non-urgent use and hospital admissions for ambulatory sensitive conditions.

Table 2.1: Measures related to Hypothesis 2.1, by Research Question

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Research question 2.1.a Do	-	nentation of sta	ndard plans dec	rease the use o	f emergency
departments for non-urgen					
Number of ED visits	NCQA - HEDIS	Use of ED visits	All	Claims / Encounters	Outcome
A i dalala an musus metalala			A.II		0
Avoidable or preventable	NYU /	Evidence of	All	Claims /	Outcome
emergency department	Billings	an avoidable		Encounters	
visits	algorithm	ED visit			
Research question 2.1.b Do admissions for ambulatory	-		ndard plans dec	rease the use o	f hospital
Number of hospital		Hospital	All	Claims /	Outcome
admissions		Admissions		Encounters	
Number of hospital days		Hospital Days	All	Claims /	Outcome
		riospitai Bays	,	Encounters	o deconic
Hospital admissions for	AHRQ PQI	Evidence of	All	Claims /	Outcome
ambulatory sensitive	and PDI	ASHA		Encounters	
conditions; avoidable or					
preventable inpatient					
hospitalizations					
Research question 2.1.c Do	es the impler	nentation of BH	I/DD Tailored P	lans decrease t	he use of
emergency departments fo	r non-urgent	use?			
Number of ED visits	NCQA -	Use of ED	All	Claims /	Outcome
	HEDIS	visits		Encounters	
Avoidable or preventable	NYU /	Evidence of	All	Claims /	Outcome
Avoidable or preventable emergency department	NYU / Billings	Evidence of an avoidable	All	Claims / Encounters	Outcome
emergency department	Billings	Evidence of an avoidable ED visit	All	Claims / Encounters	Outcome
emergency department visits	Billings algorithm	an avoidable ED visit		Encounters	
emergency department visits Research question 2.1.d Do	Billings algorithm pes the impler	an avoidable ED visit <b>nentation of BH</b>	I/DD Tailored P	Encounters	
emergency department visits Research question 2.1.d Do hospital admissions for am	Billings algorithm pes the impler	an avoidable ED visit <b>nentation of BH</b>	I/DD Tailored P	Encounters	
emergency department visits Research question 2.1.d Do hospital admissions for am Number of hospital	Billings algorithm bes the impler bulatory sens	an avoidable ED visit mentation of BH itive conditions?	I/DD Tailored P	Encounters  lans decrease t	he use of
emergency department visits Research question 2.1.d Do hospital admissions for am Number of hospital admissions	Billings algorithm bes the impler bulatory sens	an avoidable ED visit nentation of BH itive conditions? Hospital	I/DD Tailored P	Encounters  lans decrease t  Claims /	he use of
emergency department visits Research question 2.1.d Do hospital admissions for am Number of hospital admissions	Billings algorithm bes the impler bulatory sens	an avoidable ED visit mentation of BH itive conditions? Hospital Admissions	I/DD Tailored P ? All	Encounters  lans decrease t  Claims / Encounters	<b>he use of</b> Outcome
emergency department visits Research question 2.1.d Do hospital admissions for am Number of hospital admissions Number of hospital days	Billings algorithm bes the impler bulatory sens	an avoidable ED visit mentation of BH itive conditions? Hospital Admissions	I/DD Tailored P ? All	Encounters  lans decrease t  Claims / Encounters  Claims /	<b>he use of</b> Outcome
emergency department visits Research question 2.1.d Do hospital admissions for am Number of hospital admissions Number of hospital days Hospital admissions for	Billings algorithm pes the impler bulatory sens 	an avoidable ED visit mentation of BH itive conditions? Hospital Admissions Hospital Days	I/DD Tailored P P All	Encounters  lans decrease t  Claims / Encounters Claims / Encounters	he use of Outcome Outcome
emergency department visits Research question 2.1.d Do	Billings algorithm  Des the impler bulatory sens AHRQ PQI	an avoidable ED visit  mentation of BH itive conditions? Hospital Admissions Hospital Days  Evidence of	I/DD Tailored P P All	Encounters  lans decrease t  Claims / Encounters  Claims / Encounters  Claims / Claims /	he use of Outcome Outcome
emergency department visits Research question 2.1.d Do hospital admissions for am Number of hospital admissions Number of hospital days Hospital admissions for ambulatory sensitive conditions; avoidable or	Billings algorithm  Des the impler bulatory sens AHRQ PQI	an avoidable ED visit  mentation of BH itive conditions? Hospital Admissions Hospital Days  Evidence of	I/DD Tailored P P All	Encounters  lans decrease t  Claims / Encounters  Claims / Encounters  Claims / Claims /	he use of Outcome Outcome
emergency department visits Research question 2.1.d Do hospital admissions for am Number of hospital admissions Number of hospital days Hospital admissions for ambulatory sensitive conditions; avoidable or preventable inpatient	Billings algorithm  Des the impler bulatory sens AHRQ PQI	an avoidable ED visit  mentation of BH itive conditions? Hospital Admissions Hospital Days  Evidence of	I/DD Tailored P P All	Encounters  lans decrease t  Claims / Encounters  Claims / Encounters  Claims / Claims /	he use of Outcome Outcome
emergency department visits Research question 2.1.d Do hospital admissions for am Number of hospital admissions Number of hospital days Hospital admissions for ambulatory sensitive conditions; avoidable or	Billings algorithm  Des the impler bulatory sens AHRQ PQI and PDI	an avoidable ED visit  mentation of BH itive conditions  Hospital Admissions Hospital Days  Evidence of ASHA	I/DD Tailored P P All All All	Encounters  lans decrease t  Claims / Encounters  Claims / Encounters  Claims / Encounters	he use of Outcome Outcome Outcome

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Number of ED visits	NCQA -	Use of ED	All	Claims /	Outcome
	HEDIS	visits		Encounters	
Avoidable or preventable	NYU /	Evidence of	All	Claims /	Outcome
emergency department	Billings	an avoidable		Encounters	
visits	algorithm	ED visit			
Research question 2.1.f Do	es the implem	entation of spe	cialized foster c	are plans decrea	ase the use of
hospital admissions for am	bulatory sensi	itive conditions?	?		
Number of hospital		Hospital	All	Claims /	Outcome
admissions		Admissions		Encounters	
Number of hospital days		<b>Hospital Days</b>	All	Claims /	Outcome
				Encounters	
Hospital admissions for	AHRQ PQI	Evidence of	All	Claims /	Outcome
ambulatory sensitive	and PDI	ASHA		Encounters	
conditions; avoidable or					
preventable inpatient					
hospitalizations					

**Hypothesis 2.2:** The implementation of Medicaid managed care will increase the number of enrollees receiving care management, overall and during transitions in care. (Note that Hypothesis 1.4 focuses on the role AMHs specifically, whereas this Hypothesis focuses on access to care management generally and during transitions in care.)

Table 2.2: Measures related to Hypothesis 2.2, by Research Question

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Research question receiving care mar		ne implementation (	of standard plans inc	rease the numb	er of enrollees
Coordination of Care (consumer perceptions)	NQF #: 0006	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q22&Q23	Outcome
Time to SDOH Screening from PHP attribution		Number of days from enrollment to SDOH screening	PHP enrollees	Claims / Encounter data ; PHP data; NCcare360	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
•		•	of standard plans inc	rease the numb	er of enrollees
receiving care man	agement dur	Evidence of care	Beneficiaries	Claims /	Process
Receiving Care			discharges from a	Encounter	Process
Management		management	long hospital,	data; care	
during transitions			rehab, or	management	
in care			residential care	data systems	
Medication	ACO-12	Evidence of	Beneficiaries	Claims /	Process
Reconciliation	ACO-12	medication		Encounter	Process
		reconcillation	discharges from a	data	
Post-Discharge		reconcination	long hospital,	uata	
			rehab, or residential care		
Dosoorch avoction	2 2 a Daga th	a implementation a		lana inavaasa th	a mumbar of
•		•	of BH I/DD Tailored P	ians increase th	e number of
enrollees receiving Coordination of			Decemberdants	CALIDO	Outcome
	NQF #:	Respondents	Respondents to	CAHPS	Outcome
Care (consumer	0006	who always	the CAHPS	Q22&Q23	
perceptions)		received the	survey*		
		desired care or			
		service			
Time to SDOH		Number of days	PHP enrollees	Claims /	Process
Screening from		from enrollment		Encounter	
PHP attribution		to SDOH		data ; PHP	
		screening		data;	
				NCcare360	
Research question	2.2.d Does th	e implementation	of BH I/DD Tailored F	lans increase th	e number of
enrollees receiving	care manage	ment during transit	tions in care?		
Enrollees		Evidence of care	Beneficiaries	Claims /	Process
Receiving Care		management	discharges from a	Encounter	
Management			long hospital,	data; care	
during transitions			rehab, or	management	
in care			residential care	data systems	
Medication	ACO-12	Evidence of	Beneficiaries	Claims /	Process
Reconciliation		medication	discharges from a	Encounter	
Post-Discharge		reconcillation	long hospital,	data	
			rehab, or		
			residential care		
Research question	2.2.e Does th	e implementation of	of specialized foster of	care plans increa	se the
•		are management?	-	-	

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Coordination of Care (consumer perceptions)	NQF #: 0006	Respondents who always received the desired care or service	Respondents to the CAHPS survey*	CAHPS Q22&Q23	Outcome
Time to SDOH Screening from PHP attribution		Number of days from enrollment to SDOH screening	PHP enrollees	Claims / Encounter data; PHP data; NCcare360	Process
<u> </u>		e implementation o agement during trar	f specialized foster on sitions in care?	are plans increa	se the number
Enrollees Receiving Care Management during transitions in care		Evidence of care management	Beneficiaries discharges from a long hospital, rehab, or residential care	Claims / Encounter data; care management data systems	Process
Medication Reconciliation Post-Discharge	ACO-12	Evidence of medication reconcillation	Beneficiaries discharges from a long hospital, rehab, or residential care	Claims / Encounter data	Process

Note: A measure of care management use is under development and expected to be added as an additional metric for this outcome.

**Hypothesis 2.3**: The implementation of Medicaid managed care will reduce Medicaid program expenditures.

Table 2.3: Measures related to Hypothesis 2.3, by Research Question

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Research question 2 expenditures?	3.a Does the imple	mentation of standar	rd plans reduce Me	dicaid prog	ram
Total Expenditures to	the	Total Medicaid	PHP	Claims /	Outcome
Medicaid program a	nd	expenditures	enrollees	Encounter	-
components				data	

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Out-of-pocket costs to		OOP expenditures	PHP	Claims /	Outcome
Medicaid enrollees			enrollees	Encounter	
		Value of Medicaid	DUD	data	0
Costs of Medicaid funded			PHP enrollees	Claims / Encounter	Outcome
services and components		services, using FFS	enronees	data	
Research question 2.3.b Do	nes the implen	weights	ailored Plans rec		4
program expenditures?	ses the implen		anoreu Fians let	iuce ivicultai	u
Total Expenditures to the		Total Medicaid	TP enrollees	Claims /	Outcome
Medicaid program and		expenditures		Encounter	
components				data	
Out-of-pocket costs to		OOP expenditures	TP enrollees	Claims /	Outcome
Medicaid enrollees				Encounter	
				data	
Costs of Medicaid funded		Value of Medicaid	TP enrollees	Claims /	Outcome
services and components		services, using FFS		Encounter	
		weights		data	
Research question 2.3.c Do program expenditures?	es the implen	nentation of specialized	foster care plar	is reduce Me	edicaid
Total Expenditures to the		Total Medicaid	PHP	Claims /	Outcome
Medicaid program and		expenditures	enrollees	Encounter	
components				data	
Out-of-pocket costs to		OOP expenditures	PHP	Claims /	Outcome
Medicaid enrollees			enrollees	Encounter	
				data	
Costs of Medicaid funded		Value of Medicaid	PHP	Claims /	Outcome
services and components		services, using FFS	enrollees	Encounter	
		weights		data	

**Hypothesis 2.4**: The implementation of standard and tailored plans will increase provider satisfaction and participation in the Medicaid program

Table 2.4: Measures related to Hypothesis 2.4, by Research Question

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Research question 2.4.a	Does the imp	lementation of	standard plans in	crease provide	er satisfaction?
Overall Provider	UNC*	Measures of	Medicaid	Provider	Outcome
Satisfaction		Satisfaction	Providers	Survey	

Research question 2.4.b Ethe Medicaid program?	oes the imp	lementation of	standard plans	increase provide	r participation in
Provider participation in	UNC*	Number of	Medicaid	Claims /	Outcome
Medicaid (several		Medicaid	Providers	Encounter	
measures, by quantity		enrollees			
of participation, and by					
provider type)					
Research question 2.4.c D satisfaction?	oes the imp	lementation of E	3H I/DD Tailore	ed Plans increase	provider
Overall Provider	UNC*	Measures of	Medicaid	Provider	Outcome
Satisfaction		Satisfaction	Providers	Survey	
Research question 2.4.d E participation in the Medic	·=		BH I/DD Tailore	ed Plans increase	provider
Provider participation in	UNC*	Number of	Medicaid	Claims /	Outcome
Medicaid (several		Medicaid	Providers	Encounter	
measures, by quantity		enrollees			
of participation, and by					
provider type)					
Research question 2.4.e D satisfaction?	oes the imp	lementation of	specialized fost	er care plans inc	rease provider
Overall Provider	UNC*	Measures of	Medicaid	Provider	Outcome
Satisfaction		Satisfaction	Providers	Survey	
Research question 2.4.f D participation in the Medic	•		pecialized fost	er care plans incr	ease provider
Provider participation in	UNC*	Number of	Medicaid	Claims /	Outcome
Medicaid (several		Medicaid	Providers	Encounter	
measures, by quantity		enrollees			
of participation, and by					
provider type)					

<sup>\*</sup> Measures under development by Evaluation Team and/or other contractors

**Hypothesis 3.1**: Expanding coverage of SUD services to include residential services furnished in institutions for mental disease (IMD) as part of a comprehensive strategy will result in improved care quality and outcomes for patients with SUD.

Table 3.1: Measures related to Hypothesis 3.1, by Research Question

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
	.1.a Does th	e expanded coverage	of SUD services i	ncrease the qua	lity of care for
patients with SUD? Initiation and	NOT#.	Initiation of CUID	^ delegacet end	Claima /	Dragons
	NQF#:	Initiation of SUD	Adolescent and	Claims / Encounter	Process
Engagement of	0004/	treatment	adult		
SUD Treatment+	NCQA - HEDIS		beneficiaries with a new episode of SUD	data	
Continuity of	NQF#:	MAT use of 180+	Those with a	Claims /	Process
Pharmacotherapy	3175	days	diagnosis of	Encounter	
with OUD		•	OUD and MAT	data	
Percent of		Evidence of an	Those with a	Claims /	Process
diagnosed		SUD treatment	current	Encounter	
beneficiaries who		service	diagnosis of	data	
receive a			SUD		
treatment service					
Concurrent Use of	PQA	Contemporaneous	Adults without	Claims /	Process
Prescription	•	use of opioids and	a cancer	Encounter	
Opioids and		benzodiazepines	diagnosis and	data	
Benzodiazepines		1	not in hospice with two or more prescriptions of opioids with		
			a supply of		
			over 15 days		
Research question 3 with SUD?	.1.b Does th	e expanded coverage	e of SUD services i	mprove outcom	es for people
Percent of SUD		Evidence of	Adults with a	Claims /	Outcome
diagnosed		psychosocial	current	Encounters	
beneficiaries who		service for SUD	diagnosis of		
receive a SUD			SUD		
treatment service					
Death rate from			Adult	Claims /	Outcome
overdose			beneficiaries with SUD diagnoses	Encounter data linked with death certificate data	

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Death rate from overdose post-release			Adult beneficiaries released from prison	Death Certificate data linked with DOC data and Medicaid enrollment, claims, and encounters	Outcome

**Hypothesis 3.2:** Expanding coverage of SUD services to include residential services furnished in IMDs as part of a comprehensive strategy for treating SUD will increase the use of MAT and other opioid treatment services and decrease the long-term use of opioids.

In contrast to Hypothesis 1.2, this hypothesis and Hypothesis 3.1 examine the use of SUD services and quality of care as a result of changes in the SUD delivery system rather than the implementation of managed care. This distinction will be further described in the Methods sections below.

Table 3.2: Measures related to Hypothesis 3.2, by Research Question

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
Research question	n 3.2.a Does th	e expanded cove	rage of SUD services i	ncrease the use	of MAT?
Number of providers with DEA DATA 2000 waivers		·	NC licensed providers	NC Licensure data / DEA DATA 2000 waiver data	Process
Number of providers with DEA DATA 2000 waivers who have written prescriptions for Medicaid enrollees for MAT			NC licensed providers with DEA waivers	CSRS / Medicaid claims	Process
Percent of enrollees diagnosed with	CMS	Receipt of MAT	Enrollees age 12 and above with OUD diagnosis	Claims / Encounter data	Process

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome
OUD receiving			and/or opioid		
MAT			poisoning code		
		•	rage of SUD services i opriate level of care?		of non-
Percent of		Evidence of	Enrollees age 12	Claims /	Process
enrollees		psychosocial	and above with	Encounter	
diagnosed with		service for	OUD diagnosis	data	
OUD receiving		OUD	and/or opioid		
non-medication			poisoning code		
opioid					
treatment					
services					
ED visits for	NQF: 2605	Evidence of 1+	Children age 12	Claims /	Process
SUD-related		ED visits for	and over and	Encounter	
diagnoses and		SUD	adults with SUD	data	
specifically for					
OUD (2					
measures)					
IP visits for SUD		Evidence of 1+	Children age 12	Claims /	Process
and specifically		IP visits for	and over and	Encounter	
for OUD		SUD	adults with SUD	data	
Research question term use of opioid		e expanded cove	rage of SUD services o		bability of long-
Long-Term Use		TBD	Beneficiaries with	Claims /	Outcome
of Opioids			opioid use	Encounters	
Use of Opioids	NQF#:2940/	Evidence of	Adults without	Claims /	Outcome
at High Dosage	PQA	opioid use of	Cancer, with two	Encounter	
in Persons		greater than	or more	data	
without Cancer		120mg for 90	prescription claims		
		consecutive	for opioids filled on		
		days or longer	at least two		
			separate days, for		
			which the sum of		
			the days supply is		
			greater than or		
			equal to 15.		

**Hypothesis 3.3:** Expanding coverage of SUD services will result in no changes in total Medicaid costs for people with SUD diagnoses, increases in Medicaid costs on SUD IMD services, increases in SUD pharmacy, outpatient, and rehabilitative costs, and decreases in acute care crisis-oriented, inpatient, ED, long-term care and other SUD costs.

Table 3.3: Measures related to Hypothesis 3.3, by Research Question

Measure	Measure	Numerator	Denominator	Data	Process /		
	custodian			Sources	Outcome		
Research question 3.3a Does the expanded coverage of SUD services change total Medicaid costs?							
Total Expenditures		Total Medicaid	People with	Claims /	Outcome		
to the Medicaid		expenditures	SUD diagnoses	Encounter			
program				data			
Costs of Medicaid		Value of	People with	Claims /	Outcome		
funded services		Medicaid	SUD diagnoses	Encounter			
		services, using		data			
		FFS weights					
Research question 3		•	of SUD services of	hange out-of-po	ocket costs to		
Medicaid enrollees	with an SUD						
Out-of-pocket		OOP	People with	Claims /	Outcome		
costs to Medicaid		expenditures	SUD diagnoses	Encounter			
enrollees				data			
Research question 3		•		ncrease Medicai	d costs on SUD		
IMD services, SUD p	harmacy, out	tpatient, and rehabi	litative costs?				
Expenditures to		Total Medicaid	People with	Claims /	Outcome		
the Medicaid		expenditures	SUD diagnoses	Encounter			
program				data			
components							
Costs of Medicaid		Value of	People with	Claims /	Outcome		
funded services		Medicaid	SUD diagnoses	Encounter			
components		services, using		data			
		FFS weights					
Research question 3.3d Does the expanded coverage of SUD services decrease Medicaid costs on							
acute care crisis-orio	ented, inpatio	<u> </u>					
Expenditures to		Total Medicaid	People with	Claims /	Outcome		
the Medicaid		expenditures	SUD diagnoses	Encounter			
program				data			
components							
<b>Costs of Medicaid</b>		Value of	People with	Claims /	Outcome		
funded services		Medicaid	SUD diagnoses	Encounter			
components		services, using		data			
		FFS weights					

Measure	Measure custodian	Numerator	Denominator	Data Sources	Process / Outcome			
Research question 3	Research question 3.3e Does the expanded coverage of SUD services decrease Medicaid spending on							
non-SUD services for	or people with	an SUD diagnosis?						
<b>Expenditures to</b>		Total Medicaid	People with	Claims /	Outcome			
the Medicaid		expenditures	SUD diagnoses	Encounter				
program				data				
components								
<b>Costs of Medicaid</b>		Value of	People with	Claims /	Outcome			
funded services		Medicaid	SUD diagnoses	Encounter				
components		services, using		data				
		FFS weights						

# C. Methodology

### 1. Evaluation Design

The evaluation will use a mixed-methods approach to testing the evaluation hypotheses. The quantitative analyses will use a difference-in-differences approach to the extent possible, as described below. This approach will be informed by the qualitative analyses by triangulating results from provider interviews and surveys and discussing preliminary results with providers and other stakeholders.

#### 2. Qualitative Evaluation Plan

#### a. **Purpose**

The qualitative evaluation will examine perspectives from primary care and specialist providers including family medicine, internal medicine, pediatrics, and Ob/Gyn, behavioral health specialists, community based organizations (CBOs) (e.g., focusing on food and transportation accessibility), including those in Pilot networks, and in Pilot regions, as well as others, state health agency officials, and Prepaid Health Plans (PHPs) impacted by the NC Medicaid transformation. This examination will reveal detailed insights into the transformation that are not easily captured through claims and surveys; for example, how providers are preparing for the transformation and what can be done to improve their satisfaction with the Medicaid program. In addition to having standalone value, the qualitative evaluation, when combined with claims and survey analysis, enables a mixed methods evaluation design. A key strength of the mixed methods design is that it allows us to triangulate quantitative and qualitative approaches, thereby leveraging the strengths while minimizing the weaknesses of each. Quantitative approaches allow for establishing trends and levels of metrics and statistical significance of relationships between variables, whereas qualitative findings allow for in-depth exploration of how activities are performed and why relationships between variables exist.

Analyses of the qualitative data, along with particular stories contained in that data set, may provide additional hypotheses to test using the quantitative data sources and will be useful for developing explanations for the patterns we find in the quantitative analyses. Similarly, relationships observed among variables in the quantitative data analyses may be useful when inferring the extent to which findings from the qualitative analyses are likely to be generalizable.

In this evaluation, the qualitative analysis will enhance claims and survey analyses through collection of additional data from providers as well as data from stakeholders not reached directly by the survey or claims (e.g., health system administrators, support staff, patients). The qualitative evaluation serves both *exploratory* and *explanatory* purposes that will both inform and explain findings from the claims and survey analysis.

The *exploratory* purpose of the qualitative analysis will inform provider satisfaction surveys after waiver implementation has begun and potentially additional outcomes to examine in the claims analysis. For example, themes identified through semi-structured interviews with primary care providers about their satisfaction with the Medicaid program could inform development of survey items about the drivers of provider satisfaction, such as support received from plans, changes in reimbursement, and access to behavioral specialists (increased/decreased).

The *explanatory* purpose of the qualitative evaluation will build upon the initial and subsequent survey and claims analyses by generating explanations for these results that cannot be generated through quantitative analyses alone—typically because quantitative explanatory measures are not available or are insufficient to yield insights on key outcomes of interest. More specifically, the qualitative analysis will examine why hypotheses were or were not supported from quantitative analyses. For example, qualitative analyses will reveal insights into how "successful" providers and/or practices achieved their success. As another example, qualitative analyses could identify strategies for increasing provider satisfaction with Medicaid.

Specifically, the qualitative analysis will focus on exploratory and explanatory evaluation of the hypotheses listed in Table 4:

Table 4: Hypotheses Examined by Qualitative Evaluation


	Stakeholder Interviews				
Hypotheses	Physician Practices	Behavioral Health	Commun ity- based organizat ions	State Health Agencies	Prepaid Health Plans
<b>H1.1</b> : The implementation of Medicaid managed care will	х	х			х

increase access to care, the quality of care, and health outcomes.			Х	Х	
H1.2: The implementation of Medicaid managed care will increase the rate of use of behavioral health services at the appropriate level of care and improve the quality of behavioral health care received.	X	x	х	x	х
H1.4: Implementation of Advanced Medical Homes will increase the delivery of care management services and will improve quality of care and health outcomes.	х	x		x	
H2.1: The implementation of Medicaid managed care will decrease the use of emergency departments for non-urgent use and hospital admissions for ambulatory sensitive conditions.	х	x		х	х
H2.2: The implementation of Medicaid managed care will increase the number of enrollees receiving care management, overall and during transitions in care.	х	х		х	х
H2.4: The implementation of Medicaid managed care will increase provider satisfaction and participation in the Medicaid program	х	х		х	
<b>H3.1:</b> Expanding coverage of SUD services to include residential services furnished in IMDs as part of a comprehensive strategy for treating SUD will result in		х	х		х

improved care quality and			
outcomes for patients with SUD.			
<b>H3.2:</b> Expanding coverage of SUD			
services to include residential			
services furnished in IMDs as part			
of a comprehensive strategy for			
treating SUD will increase the use	Х	Х	Х
of MAT and other appropriate			
opioid treatment services and			
decrease the long-term use of			
prescription opioids.			

Finally, the qualitative evaluation also will help ensure validity of conclusions through convergence or confirmation of quantitative results (Figure 1). Convergence in the results from the qualitative and quantitative analyses will provide stronger support for our findings, whereas any divergences in the results of the analyses will be useful for tempering interpretations of findings and guiding subsequent research efforts. For example, are quantitative measures of network adequacy and qualitative data on provider perceptions of network adequacy convergent or divergent? Convergence in the results will provide stronger support for the findings, whereas divergence in the results will inform interpretations of findings and suggest areas to examine in more depth in subsequent years of the evaluation.

Figure 1: Integration of Quantitative and Qualitative Methods



## b. Sample

We will recruit a sample of provider practices to follow during the life of the evaluation. This approach will facilitate a detailed examination into whether/how external circumstances (e.g., support provided by the plans, patient needs, community resources) change over time as well as how providers adjust to the transformation during the early implementation phase and the longer term. Our sample will include approximately 36 physician practices from across the

state, with representation from each of the 6 regions (i.e., approximately 6 practices from each region). Within each region we plan to recruit family medicine, internal medicine, pediatrics, and Ob/Gyn practices. In addition, we will recruit behavioral health specialists and representatives from CBOs from each region that interviewees at the physician practices identify as resources for their Medicaid patients.

Because there is value in assessing perceptions and experiences over time, we plan to interview participants 2-3 times during the project period (e.g. providers every two years, state agencies and health plans every 2-3 years). On average, we will conduct approximately 50 individual interviews in each of the first 6 years of the project, for a total of approximately 314 interviews. The rationale for approximately 50 interviews is that we plan to interview 1 provider and 1 administrative/nursing staff member for each practice and approximately 1 behavioral health and/or CBO representative identified by each practice. We may find a need to interview more than 2 representatives of some practices (e.g., if the practice has many providers). Alternatively, we may not need to interview a behavioral health specialist or CBO representative identified by each practice because some practices may identify the same behavioral health specialists or CBOs as key resources for their patients.

In addition, we will adjust our provider sampling frame to reflect changes in the transformation plan. For example, we will ensure that there is provider representation from each of the tailored plan regions once that element of the transformation plan has been implemented. We will use a purposive sampling approach to account for contextual factors within each region of the state. For example, we may select more practices in some regions than others to account for factors that contribute to the complexity of caring for the Medicaid population (e.g., greater number of plans available) as well as practices that have partnered with CINs as well as those that have not.

In addition to physician practices, behavioral health services, and CBOs, we will conduct interviews with key informants from the state health agencies such as the Division of Health Benefits, the Division of Mental Health, and the Division of Public Health, and representatives from each of the 5 standard plans and from the tailored plans. We anticipate interviewing ~10 individual key informants from the state health agencies at two points during the evaluations—once during the first year of implementation and once approximately 2-3 years after implementation. Similarly, we will interview representatives from the heatlh plans. These interviews may be conducted with individual representatives or small groups (e.g., 2-4 PHP representatives), depending on the preference of the standard and tailored plans. Similar to the state agency interviews, representatives from each plan will be interviewed at two points during the evaluation—once during the first year of implementation and once approximately 2-3 years after implementation. Therefore, we estimate that we will conduct a total of approximately 20 interviews with SP and TP representatives.

**Table 5: Qualitative Evaluation Sample Sizes** 

Stakeholder	Interviews per Wave	Total Interviews	Incentives		
Prepaid Health Plans	<ul> <li>~5 Interviews</li> <li>Representative from each of 5 PHPs representing all 6 regions</li> <li>2 waves of interviews</li> </ul>	10	None		
Tailored Plans	<ul> <li>Thereviews</li> <li>Representative from each of the tailored plans</li> <li>Exact number to be determined based on rollout in 2021</li> <li>2 waves of interviews</li> </ul>	10	None		
State Health Agencies	<ul><li>~10 Interviews</li><li>Representatives from DHHS</li><li>2 waves of interviews</li></ul>	20	None		
Physician Practices	<ul> <li>~72 Individuals (across 36 practices)</li> <li>1 Physician</li> <li>1 Administrator (as appropriate)</li> <li>3 waves of interviews</li> </ul>	216	\$100 per interview		
Behavioral Health Specialists	<ul> <li>12-15 Individuals</li> <li>2-3 Behavioral health specialists from each region</li> <li>3 waves of interviews</li> </ul>	40	\$100 per interview		
Community Based Organizations	<ul><li>10 Individuals</li><li>1-2 Interviews per region</li><li>2 waves of interviews</li></ul>	20	\$100 per interview		
Total Sample Size = ~ 314					

#### c. Data Collection

We will conduct semi-structured interviews with representatives from practices, behavioral health specialists, CBOs, and PHPs. Individual interviews will be conducted either in person or via teleconference (e.g., Skype or Zoom). Depending on the practice's or key informant's availability, we will aim to conduct the first round of interviews in-person, in order to establish relationships and increase the likelihood of the practice's participation in future interviews. At least two researchers will attend each in-person interview. The role of the researchers will be to prompt for additional details and to take notes. Each interview will last approximately 45-60 minutes and will be digitally recorded and subsequently transcribed.

We will use an interview guide designed to capture information on such topics as practice-level readiness and capabilities for caring for Medicaid patients, support received from PHPs, and provider satisfaction with the Medicaid program and other key features of the demonstration

components such as the tailored plans and advanced medical homes. Table 6 illustrates potential interview domains that will be explored during interviews with providers and PHPs. Topics and interview questions will be developed and revised based on input from our advisory panel, preliminary findings from the provider satisfaction survey and claims analysis, and developments occurring in the NC Medicaid Transformation program (e.g. rollout of tailored plans in 2021).

Table 6: Example Topics ans Sample Interview Questions

Example Topics	Sample Interview Question
Market Context	Could you tell us about any major changes that have happened in this market in the last year?
	How has the NC Medicaid Transformation affected your local market?
Practice Readiness and Changes for Medicaid	Is your practice doing anything differently to prepare for the new Medicaid model?
	What changes in your practice structure, staffing and/or
	processes have been made since the new Medicaid model was
	implemented? If none, do you anticipate any changes in the future?
Medicaid patient load	What proportion of your practice are Medicaid patients?
	How has the transformation changed the proportion of Medicaid patients in your practice?
	Is your practice doing anything differently to meet the needs of this population?
Advanced Medical Home	What are the core components of your Advanced Medical Home?
& Care Coordination	Does your practice have plan to increase AMH level?
	Have there been any changes in the way that care coordination is being provided?
Information and Support	What kinds practice support is provided by the prepaid health
Received from PHP	plans? E.g., reports, quality or risk stratisfication data, incentives?
Satisfaction with	Have administrative or business office functions changed since the
Administrative Process	implementation? E.g. timeliness of payment, appropriateness of payment, ease of working with the PHPs?
Physician Engagement	How has the new NC Medicaid model changed your satisfaction or engagement with the Medicaid Program?
Patient Needs	In what ways do you think patients are impacted by Medicaid transformation?
	Are there certain patient needs that are not being met?
	Characteristics of patients who are not receiving care they need?
	How has access to behavioral health changed?
	How has access to behavioral health changed:  How has access to support for health-related social needs?
L	Trow has access to support for health related social fields:

Example Topics	Sample Interview Question
Perceived Effectiveness	How does the new Medicaid model compare to the previous
of Medicaid Program	models? (e.g., is care improving for patients? What changes are needed?)
	If there was one thing you could change about the program, what
	would it be?
Barriers & Facilitators	What have been the biggest barriers or challenges facing your
	practice in the past year related to Medicaid?
	What have you done to remove or address those barriers?
	What factors have been the most helpful in improving your
	experience with Medicaid this year?

### d. Data Analysis

Following standard qualitative coding techniques, we will code data segments within transcripts using labels that capture ideas contained in the data. Related codes will then be grouped into themes that highlight common perceptions, ideas, or experiences across informants. We will follow an iterative approach to analysis that involves ongoing cycles of reading and coding transcripts, reviewing the literature, and discussing findings among the research team to identify themes. Throughout the process we will use the constant comparative method comparing data with data, data with codes, codes with codes, and codes with themes, in order to construct a detailed framework of perceptions regarding the effectiveness of care coordination strategies. The research team will use a software package (e.g., NVivo version 12) to facilitate the managing and coding of qualitative data.

### 3. Quantitative Evaluation Plan

The quantitative evaluation plan will focus on the trends in and analysis of the measures outlined in Tables 1.1-3.2. We will use conduct analyses of metrics that are feasible on a monthly basis and reporting results to NC DHHS through a data dashboard to be developed as part of the Evaluation. This approach will allow for the best possible estimates in the shortest possible time, to provide feedback to DHHS and PHPs to allow for short-term quality improvements in plan delivery. We will make appropriate adjustments in the evaluation design if changes in the implementation occur (e.g., using additional time period indicators in the analyses; testing for structural breaks in the parameter estimates). The focus will be on causal modeling of each measure in an attempt to identify changes in the measure due to each aspect of the 1115 waiver. A variety of quantitative techniques will be used as described below.

# a. Difference-in-differences analysis

Through the use of a contemporaneous comparison group, described below, and preintervention data, many of the models estimated for the evaluation will follow a difference-indifferences approach.

Variables on expenditures and utilization derived from claims data will generally be updated monthly for analysis. Other variables that are from surveys or only available annually will be analyzed on an annual basis. Some metrics that are not relevant monthly, such as quality metrics with annual benchmarks (e.g., the % of eligible women receiving breast cancer screening), will be aggregated to annual measures and analyzed on a rolling basis as appropriate.

Analysis models will take the following form:

$$Y_{it} = f(\beta_0 + \beta_1 WaiverParticipant_{it} + \beta_2 Post_t + \beta_3 WaiverParticipant_{it} * Post_t + \beta_4 Z_{it} + \beta_5 Time_t) + \varepsilon_{it}$$

where i indexes individuals, t indexes time periods, Y are the process and outcome measures specified above, WaiverParticipant indicates individuals in the target population for each element of the waiver (e.g., those in the standard plans; those in the tailored plans), Post indicates the relevant post implementation period, Z are time-varying covariates, Time is a time period counter that starts from 1 during the first observation in the analysis period, and  $\varepsilon$  is the model error term. We will examine both linear models with person-level fixed effects, our preferred specification to control for time-invariant selection differences between treatment and control groups, as well as Generalized Estimating Equation (GEE) models with appropriate distributional and correlation specifications for each outcome measure. Results from all analyses will be converted to average marginal effects, which specify the natural unit increase in the outcome measure due to the implementation of the waiver component (e.g., standard plans, tailored plans, SUD waiver provisions).

### b. Regression discontinuity models

PHPs, AMHs, and/or CINs are required to implement a risk stratification system in order to indentify Medicaid and Health Choice enrollees who might benefit from care management. If a single risk score were available across plans and a single threshold for the score were used to indentify candidates for care management, then a regression discontinuity design could be implemented for research questions 1.4 evaluating care management services by examining differences in outcomes for those just below and just above the assignment threshold. However, no single risk scoring tool has been required, which may mean that dozens of different risk scoring systems and thresholds of assignment may be in play. Information on exactly which risk scoring tool will be used by PHPs, AMHs, and CINs may not be available until implementation. We will seek to gather data on these tools from PHP reporting, through

contact with plan administrators, and from DHHS, and if a small number of risk scoring systems are in use on a sufficient number of PHP enrollees to justify the use of an RD design, we will use one to evaluate the effectiveness of care management systems, as described above.

# c. Interrupted time-series analysis models

Interrupted time-series (ITS) analysis models will take the following form:

$$Y_{it} = f(\beta_0 + \beta_1 Time_{it} + \beta_2 Post_t + \beta_3 Time_{it} * Post_t + \beta_4 Z_{it} +) + \varepsilon_{it}$$

This analysis is different from difference-in-differences analyses in two ways. First, it only includes intervention observations, from pre- and post- implementation, and thus a *Treatment* indicator is not necessary as it would always equal 1. Second, it specifically tests for changes in the slope of the time trends, in addition to an average shift in the level of the outcome for each measure. We will again generate average marginal effects of the interventions on the level of each outcome and on the trends in the outcomes, but will use GEE and related techniques for modeling outcomes. Because an ITS approach is subject to confounding from events such as the availability of treatments or changes in the health services environment that occur during the post-period, it is not our preferred approach to analysis. However, it may be used for quantitative analyses when a contemporaneous comparison group is not available, such as in analyses of the provider survey. At this writing the provider survey may not contain a pre-intervention assessment due to contract delays, in which case, we would use a modified ITS approach that would examine changes in provider satisfaction over time during the demonstration years and with respect to demonstration milestones.

### d. Costs of care

Research questions 2.3 and 3.3 examine the costs care. In a fee-for-service system, identifying costs to the Medicaid program is straightforward through the use of Medicaid expenditures. In capitated systems, there are several complications to this approach. PHPs are expected to continue to pay individual providers on a fee-for-service basis, but expenditure data is not always present in encounter data as it is often perceived as proprietary. This includes the baseline services funded through NC's currently behavioral health carve-out to regional entities, as well as the state-budged IMD services. In addition, the incentives to report accurate expenditure data may be dampened under capitation, although this can be mitigated through auditing or other forms of monitoring. Finally, the costing perspective may change under capitation, since the costs of an additional service to the Medicaid program are zero when the risk for service use is assumed by a PHP. In contrast, the societal cost of service use is non-zero, but should also include other costs not typically available in claims, such as time and transportation costs.

While the gold standard in cost analysis is to take a societal cost perspective, including not only the direct payments for services, but also unreimbursed costs of care as well as time and travel costs for patients, this approach is very resource intensive to do well and requires substantial primary data collection. Relevant costs for most Medicaid policy analyses include costs to the Medicaid agency (including payments for services under fee-for-service as well as capitation payments), out-of-pocket costs to patients (co-payments), and costs to capitated health plans. We will examine costs from all three of these perspectives for the two cost hypotheses, as the data allows. That is, we will examine costs from the Medicaid agency perspective by aggregating fee-for-service payments for services outside the capitation system with capitation payments, but excluding the cost of services paid by PHPs. These costs are generally expected to decrease under capitation, but may increase with the expanded set of SUD benefits (Hypothesis 3.3). We will examine the out-of-pocket costs to Medicaid beneficiaries, as recorded in claims and encounters. These costs are hypothesized to remain constant. Finally, we will examine the costs of services provided under capitation, which is similar to a PHP perspective, had they been paying for services prior to PHP implementation. This perspective will use a fee-for-service costing approach to actual services use. If PHP expenditures are available in the encounter data, then we will use these expenditures directly, as the fee schedule for HCPCS coded services is not expected to change. If expenditures are not available from PHP encounter data, then we will append the pre-PHP fee-schedule to services delivered after PHP implementation.

Table 7: Summary Design Table for Quantitative Evaluation Metrics

Abbreviated Research Question	Location of Outcome Measures	Comparison Group	Data Sources (Data source #s from Table 6)	Analytic Methods
Hypothesis 1.1	Table 1.1	Nama (Dua (Daat)	CALIDS (E)	Into un unto d
RQ1.1.a: Effect of standard plans on access to physical health care RQ1.1.d: Effect of tailored/specialized	Table 1.1	None (Pre/Post)	-CAHPS (5), immunization registry data (11)	Interrupted time series
plans on access to physical health care		In/Out of State Controls	-Claims (1, 27), Encounters (2, 3)	Difference-in- Differences
RQ1.1.b: Effect of standard plans on the quality of care RQ1.1.e: Effect of tailored/specialized plans on the	Table 1.1	None (Pre/Post)	-CAHPS (5)	Interrupted time series
quality of care		In/Out of State Controls	Claims (1, 27), Encounters (2, 3), PHP data (9), Birth Certificate	Difference-in- Differences

Abbreviated Research Question	Location of Outcome Measures	Comparison Group	Data Sources (Data source #s from Table 6) data (12), LHD data (25)	Analytic Methods
RQ1.1.c: Effect of standard plans on outcomes RQ1.1.f: Effect of tailored/specialized plans on outcomes	Table 1.1	None (Pre/Post)	-CAHPS (5)	Interrupted time series
		In/Out of State Controls	Claims (1, 27), Encounters (2, 3), PHP data (9), Birth Certificate data (12), Death Certficate data (13), BRFSS (14), DOC (19)	Difference-in- Differences
Hypothesis 1.2				
RQ1.2.a: Effect of standard plans on appropriate use of behavioral health services RQ1.2a: Effect of standard plans on quality of behavioral health services RQ1.2c: Effect of tailored/specialized plans on appropriate use of behavioral health services RQ1.2d: Effect of tailored/specialized plans on quality of behavioral health services RQ1.2d: Effect of tailored/specialized plans on quality of behavioral health services Hypothesis 1.3	Table 1.2	In/Out of State Controls	Claims (1, 27), Encounters (2, 3), PHP data (9), Clinical and diagnositic assessment data (10), NC TOPPS (20), NSDUH (23)	Differences  Differences

Abbreviated Research Question	Location of Outcome	Comparison Group	Data Sources (Data source #s	Analytic Methods
RQ1.3a: Effect of standard plans on Rx for OUD RQ1.3b: Effect of standard plans on Services for OUD RQ1.3c: Effect of standard plans on use of opioids RQ1.3d: Effect of tailored/specialized plans on Rx for OUD RQ1.3e: Effect of tailored/specialized plans on Services for OUD RQ1.3f: Effect of tailored/specialized plans on use of opioids	Measures Table 1.3	In/Out of State Controls	rom Table 6) -Claims (1, 27), Encounters (2, 3), DEA data (16), Licensure data (15), CSRS (17), DOC (19)	Difference-in- Differences
RQ1.4a: Effect of AMH on receipt of care management RQ1.4b Effect of AMH on quality RQ1.4c Effect of AMH on outcomes  Hypothesis 2.1	AMH on receipt of care management state controls; In- Encou state controls 3), PH RQ1.4b Effect of will consist of care AMH on quality PHP enrollees management not in Tier 3 data (8 AMH on outcomes AMHs, if immulately registres powered. (11)		management data (8), immunization registry data	Difference-in- Differences
RQ2.1.a: Effect of standard plans on non-urgent ED use RA2.1.b Effect of standard plans on hospital admissions RQ 2.1.c: Effect of tailored/specialized	Table 2.1	In/Out of State Controls	-Claims (1, 27), Encounters (2, 3), PHP data (9), NC Hospital Discharge Data (21)	Difference-in- Differences

Abbreviated	Location of	Comparison	Data Sources	Analytic
Research Question	Outcome Measures	Group	(Data source #s from Table 6)	Methods
plans on non-				
urgent ED use				
RA2.1.d Effect of				
tailored/specialized				
plans on hospital				
admissions				
Hypothesis 2.2				
RQ2.2.a: Effect of	Table 2.2	None (Pre/Post)	CAHPS (5)	Interrupted
standard plans on	- consumer			time series
care management	perceptions of			
RQ2.2.c: Effect of	care			
tailored/specialized	coordination			
plans on care				
management				
RQ2.2.a: Effect of	Table 2.2	None	-NCcare360 (7)	Descriptive
standard plans on	- Time to SDOH			
care management	Screening from			
RQ2.2.c: Effect of	PHP attribution			
tailored/specialized				
plans on care				
management				
RQ2.2.a: Effect of	Table 2.2	In/Out of State	-Claims (1),	Difference-in-
standard plans on		Controls	Encounters (2,	Differences
care management			3), PHP data (9),	
RQ2.2.b: Effect of			NC Hospital	
standard plans on			Discharge Data	
care management			(21)	
during transitions				
RQ2.2.c: Effect of				
tailored/specialized				
plans on care				
management				
RQ2.2.d: Effect of				
tailored/specialized				
plans on care				
management				
during transitions				
Hypothesis 2.3	l			

Abbreviated Research Question	Location of Outcome Measures	Comparison Group	Data Sources (Data source #s from Table 6)	Analytic Methods
RQ2.3.a Effect of	Table 2.3	In/Out of State	Claims (1, 27),	Difference-in-
standard plans on		Controls	Encounters (2,	Differences
Medicaid			3), MEPS (22)	
expenditures				
RQ2.3.b Effect of				
tailored/specialized				
plans on Medicaid expenditures				
Hypothesis 2.4				
RQ2.4.a Effect of	Table 2.4	None (Pre/Post	Provider Survey	Interrupted
standard plans on	Table 2.4	or Post-only)	(6)	time series
provider		or rost omy,	(0)	time series
satisfaction				
RQ2.4.c Effect of				
tailored/specialized				
plans on provider				
satisfaction				
RQ2.4.b Effect of	Table 2.4	In/Out of State	Claims (1, 27),	Difference-in-
standard plans on		Controls	Encounters (2,	Differences
provider			3),	
participation				
RQ2.4.b Effect of				
tailored/specialized				
plans on provider				
participation				
Hypothesis 2.5	T			
RQ 2.5.a Effect of	Table 2.5	Pre/Post	Provider survey	Interrupted
managed care on			(6)	Time Series
provider				
satisfaction	T-1-1- 2 F	1. (0. 1 (0 1.	Cl-1 (4, 27)	D:((
RQ 2.5.b Effect of	Table 2.5	In/Out of State	Claims (1, 27),	Differences-in-
managed care on		Controls	Encounters (2,	differences and
provider participation			3)	Interrupted Time Series
Hypothesis 3.1				Tille Selles
RQ3.1.a Effect of	Table 3.2	In/Out of State	Claims (1, 27),	Difference-in-
expanded SUD	Table 3.2	Controls	Encounters (2,	Differences
services on quality		201101013	3), IMD data (4),	Differences
of care for SUD			DOC (19), Death	
5. care 101 50B	<u> </u>		200 (15), Death	

Abbreviated Research Question	Location of Outcome Measures	Comparison Group	Data Sources (Data source #s from Table 6)	Analytic Methods
RQ3.1.b Effect of expanded SUD			Certificate data (13)	
services on outcomes for SUD				
Hypothesis 3.2				
RQ3.2.a Effect of expanded SUD services on Rx for OUD RQ3.2.b Effect of expanded SUD services on Sevices for OUD RQ3.2.c Effect of expanded SUD services on opioid use	Table 3.1	In/Out of State Controls	Claims (1, 27), Encounters (2, 3), DEA data (16), Licensure data (15), CSRS (17)	Difference-in- Differences
Hypothesis 3.3				
RQ3.3 a-f Effect of expanded SUD services on total costs and cost components for people with SUD diagnoses	Table 3.3	In/Out of State Controls	Claims (1, 27), Encounters (2, 3), MEPS (22)	Difference-in- Differences

# e. Target and Comparison Populations

# i. Target Populations

For most quantitative analyses, target populations will be defined from enrollment, claims, and encounter data. Analyses will be conducted at the beneficiary level for most measures, although re-admission analyses will be conducted at the hospital stay level. Many measures examine the full population of Medicaid beneficiaries, which will include those enrolled in Medicaid managed care for the relevant period (month, quarter, or year). Many hypotheses are specific to either populations in tailored plans or in standard plans, and thus target populations will be limited to those enrolled in these plans for the period enrolled. For baseline (pre-implementation, prior to Nov 1, 2019 for standard plans or 2021 for tailored or specialized plans) data, prior to attribution of enrollees to specific PHPs and benefits, we will use the tailored and specialized plan definitions from the Medicaid Managed Care Final Policy

Guidance: Behavioral Health and Intellectual / Developmental Disability Tailored Plan Eligibility and Enrollment document<sup>5</sup>, which are based on diagnoses and other information from the claims and enrollment files. Some measures are relevant only for subpopulations, such as beneficiaries with diabetes. We will use diagnoses available in the claims and encounter data, acknowledging that this approach is efficient from an evaluation cost perspective, but will undercount individuals with the diagnosis, since not all diagnoses are recorded in claims; this is especially true for behavioral health diagnoses. This will have the result of biasing the estimation sample towards those with either longer term or more acute illness, but makes the estimates comparable to the numerous other studies that use claims data for identification.

We will conduct a limited number of subpopulation analysis, based on region, age, sex, race/ethnicity, and disability status as well as by key population groups where feasible, in order to contribute to the Disparity Reporting and Tracking from the State's Quality Strategy. We will also stratify some analyses on specific PHPs as motivated by the qualitative and survey analyses in order to between understand differences by characteristic of PHPs (e.g., if some subset of PHPs have a common set of initiatives around tobacco cessation, we will run analyses around tobacco-use outcomes for beneficiaries attributed to these PHPs).

### ii. Comparison Populations

Because of the rapid changes in the Medicaid and scientific environments, a contemporaneous control group is desirable. Our quantitative analysis uses several different control groups for analyses, based on data availability and feasibility, as described below. Control groups will be adjusted for differences in observable characteristics through methods such as inverse probability of treatment weights (also referred to as propensity score methods), coarsened exact matching, and/or synthetic control methods.

#### 1. Within-state controls

We will use two sets of within-state controls drawn from the Medicaid and Health Choice population: enrollees that meet the criteria for PHP enrollment before the PHPs are implemented, and enrollees in the Phase II regions, who will have their PHPs coverage delivered with a 4-month lag. The second approach is exploratory only and not critical to the evaluation design, and viable as a control group only for a subset of metrics that are expected to be immediately influenced by managed care implementation (e.g., medications, expenditures).

The groups that are either exempt from managed enrollment or will be enrolled in the behavioral health intellectual / developmental disability tailored or specialized foster care plans by Demonstration Year 3 are not an ideal comparison group, because they consist of individuals who may have distinct patterns of care from those enrolled in managed care, such as Dual-

\_

<sup>&</sup>lt;sup>5</sup> https://files.nc.gov/ncdhhs/BH-IDD-TP-FinalPolicyGuidance-Final-20190318.pdf

enrollees, those with partial Medicaid benefits, or those with high behavioral health service needs.

We are working towards the inclusion of one additional set of in-state controls, which would be drawn from privately insured NC Blue Cross / Blue Shield (BCBSNC) enrollees, to the extent a similar control group can be identified and with permission from the data custodian. These data have been requested; once they are in hand, we will explore the trends in the outcome variables relevant for those in the standard plans to determine whether the trends in the baseline period are similar between those in the standard plans and BCBSNC enrollees.

# 2. Out-of-state controls

The Evaluation Team is also exploring the use of comparison Medicaid enrollees from one or more other states' Medicaid programs. While these controls would be ideal to control for changes in national or regional events, such as changes in the labor market that may expand or contract the Medicaid population, changes in the scientific knowledge base and FDA-approved drugs or devices, there are a number of downsides to using out-of-state comparisons. First, it would be ideal to identify one state that has similar levels and trends in outcome metrics during the baseline period and thus serves as a counterfactual to the changes from NC's Medicaid waiver. However, due to the considerable heterogeneity among states in characteristics of their Medicaid programs, provider supply, and patient populations, it is close to impossible to identify a state that meet this requirement. In addition, as described above, the first step in the analysis would be to identify whether the trends in each of the measures specified in Tables 1.1-3.2 above are similar between the intervention and comparison groups. In order to do this, we would need to have the states' data in hand and to run algorithms to generate analytic files from each of these states, not knowing whether the states' data will have similar trends, leading to a non-zero probability of rejection. This is a fairly costly proposition with considerable uncertainty that the investment will pay off, if the trends are not similar. Finally, acquiring another state's data takes relationship-building and a considerable investment in programming effort, as each state's data can differ substantially in format and content. Acquiring data from CMS through MSIS or T-MSIS data sources that are contributed by states and further cleaned by CMS and its subcontractor is being explored as a possibility, although this approach adds a considerable time lag to comparison data, meaning that the full difference-in-differences model described above can only be implemented with a likely 1-3 year lag (e.g., analysis of the first year post-implementation would only be available at least 1-3 years later). Finally, another option under consideration is the use of one or more comparison states through a distributed network approach, which would not allow pool analysis, but would allow the comparison of trends across states in a limited number of outcome measures. AcademyHealth's State University Partnership Learning Network (SUPLN) is investigating the use of a distributed network for our and other states' 1115 waiver evaluations.

In collaboration with NC DHHS, the Evaluation Team is actively involved in discussions with Oklahoma to examine the comparability of Medicaid patterns of utilization

between the two states. Initial comparisons indicate that the relative per enrollee expenditures between the two states are similar, potentially indicating the levels of utilization may also be similar. In addition, conversations with the SUPLN members is progressing as well, as a potential back up plan.

Finally, for national data sets such as the Behavioral Risk Factor Surveillance System (BRFSS), we will draw contemporaneous controls from other states, segmented by their managed care implementation status, thus comparing North Carolina respondents' values to respondents in other states that have and have not yet implemented a capitated managed care program.

#### d. Evaluation Period

The evaluation study period runs from January 1, 2014 – October 31, 2024, five years prior to Demonstration Year 1, and through the end of the demonstration. There are at least four distinct time periods that we will use for the quantitative evaluation, described below. If the demonstration is altered in a substantial way after its initial approval, these periods may be modified.

We will consider the baseline time period from January 1, 2014-June 30, 2019, prior to expected implementation of the SUD components of the waiver. An additional baseline time period of July 1, 2019 – January 31, 2020 is relevant for the implementation of the standard plans. For most of the analyses for Goals 1 and 2, we will limit the baseline analysis period to be five years prior to PHP implementation, February 1, 2015-January 31, 2020. The third relevant period is during the implementation of standard plans only, beginning February 1, 2020 – June 30, 2021. During this time period, the population that is to be enrolled in tailored and specialized plans will continue to be in fee-for-service coverage for medical care, and will continue to receive behavioral health care and care for I/DD through the LME/MCOs, which will continue to be paid as Prepaid Inpatient Healthcare Plans. Populations excluded from LME-MCOs (e.g., NC Health Choice, children under age 3) will continue to obtain behavioral health services through FFS. During the third evaluation time period, the standard plans will be phased in on a regional basis, with a 4-month lag between implementation in the Phase I regions and implementation in the Phase II regions. In addition, during the third evaluation time period, the ECMOS Pilots will be phased in. Finally, the fourth evaluation time period will reflect the full implementation of the standard, tailored, and specialized plans, and is expected to run from the fall of 2021 – October 31, 2024.

# e. ECMOS Pilots and interactions among waiver components

Individuals who are enrolled in a PHP in a selected pilot region and are eligible for pilot services will be potentially affected both by the transition to the PHP as well as by the additional pilot services. In addition, pilot service receipients may be in a practice that is designated as an Advanced Medical Home, and thus may receive care management services from their AMH, PHP, or other local management entity. Fortunately, these events happen at different time

periods at the initial launch of managed care (SP and AMH implementation is Feburary 1, 2019, 2020 while pilot services will begin to be delivered in late 2020 or early 2021). Pilot services will be examined in a separate evaluation and thus the evaluation methods will not be described here. However, pilot enrollees will be included in all analyses of PHP enrollees. In addition, once pilot enrollees can be identified through their receipt of services, we will be able to conduct additional analyses of PHPs and other components of the waiver excluding pilot enrollees in order to be able to tease out the effect of the PHP without the additional effects of pilot services.

Our general strategy allows for isolation of separate effects of many but not all of the waiver components, generally based on temporal separation of waiver components, or on selection criteria for specific components, such as the regional implementation of the pilots or the identification of AMH practices. Some waiver components that will be implemented contemporaneously, such as AMHs that launch at the same time as PHPs, for example, may not allow for identification of separate effects. For example, if most PHP enrollees are also receiving care from an AMH, we may not be able to identify the separate effects due to PHPs independent of AMHs. We will constantly stay up-to-date on waiver and managed care events, and will revise evaluation analyses accordingly to provide the most policy relevant results on the specific components of the waiver and managed care program.

#### D. Data Sources

Table 8: Data Sources Requested for 1115 Waiver Evaluation

Data Source		Data Custodian	Periodicity	Dates Requested	Frequency of data needed
1.	FFS Claims data	DHHS	Continuous	January 1, 2014 – Oct 31, 2024	Monthly
2.	LME/MCO encounter data <sup>a, b</sup>	DHHS	Continuous	January 1, 2014 – June 30, 2021 <sup>c</sup>	Monthly
3.	PHP encounter data <sup>a, b</sup>	PHPs	Continuous	February 1, 2020 – Oct 31, 2024	Monthly
4.	State Operated Facility utilization (public "IMD" utilization) b	State Operated Facilities	Continuous	January 1, 2014 – Oct 31, 2024	Monthly
5.	CAHPS	DHHS will contract with an EQRO to implement the Adult and Child Version of the	Annual	2014 - 2024	Annually, or as administered

Dat	a Source	Data Custodian	Periodicity	Dates Requested	Frequency of data needed
		Health Plan Survey annually			
6.	Provider Surveys <sup>d</sup>	UNC-CH	Annual	2019 - 2024	
7.	NC Resource Platform / NCCare360 / pilot data b	DHHS/Unite US/Foundation for Health Leadership & Innovation	Continuous	2019-2024	Quarterly
	Care management data b	DHHS / CCNC / PHPs / LHD / AMHs / TP care management entities	Continuous	2014 - 2024	Quarterly
9.	PHP data - Plan data outside of encounter data that is reported to DHHS, include provider registries/networks	PHPs	Annual	February 1, 2020 – October 31, 2024	Annual or as reported
10.	Comprehensive Clinical and Diagnostic Assessments	PHPs	Continuous	February 1, 2020 – October 31, 2024	Monthly or as reported
11.	Immunization registry data <sup>b</sup>	DPS	Continuous	January 1, 2014 – Oct 31, 2024	Quarterly
12.	Birth Certificate Data <sup>b</sup>	State Center for Health Statistics	Continuous	January 1, 2014 – Oct 31, 2024	Annually
13.	Death Certificate Data <sup>b</sup>	State Center for Health Statistics	Continuous	January 1, 2014 – Oct 31, 2024	Annually
14.	BRFSS <sup>d</sup>	CDC / Publicly available	Annual	2014 - 2024	Annually
15.	Active, licensed providers in NC with prescribing privileges) (MD, DO, NP, PA) d	Either NC Licensure data or NPPES	Continuous	2014 - 2024	Annually
16.	Number of providers with DEA DATA 2000 Waivers d	DEA (requires subscription)	Monthly	2014 - 2024	Monthly

Data Source	Data Custodian	Periodicity	Dates Requested	Frequency of data needed
17. Controlled Substances Reporting System <sup>b</sup>	DHHS	Continuous	January 1, 2014 – Oct 31, 2024	Monthly
18. Practice Grouper, if not available through DHHS (tentative, not included in budget) d	IQVIA	TBD	January 1, 2014 – Oct 31, 2024	Quarterly
19. NC Department of Corrections Data (tentative, not included in budget) b	NC DOC	Continuous	January 1, 2014 – Oct 31, 2024	Quarterly
20. NC Treatment Outcomes and Program Performance System (NC-TOPPS) b [tentative, subject to conversation with Data Custodian]	NC DHHS	Continuous	January 1, 2014 – June 30, 2024 Oct 31, 2024	Annually
21. NC Hospital Discharge Data <sup>d</sup>	DHSR	Annual	2014 - 2024	Annually
22. Medical Panel Expenditure Survey d	AHRQ	Annual	2014 - 2024	Annually
23. National Survey on Drug Use and Health d	SAMHSA	Annual	2014 - 2024	Annually
24. Medicare data for dual eligibles <sup>b</sup>	CMS to DHHS	Continuous	January 1, 2014 – Oct 31, 2024	Monthly
25. Data from local health departments related to high risk maternity and peds populations b	LHDs	Continuous	January 1, 2014 – Oct 31, 2024	Monthly
26. State surveys related to surveys related to BH/SUD and I/DD	DHHS	Annual	2014 - 2024	Annually

<sup>&</sup>lt;sup>a</sup> Encounter data are assumed to have actual payment information to service providers.

<sup>&</sup>lt;sup>b</sup> Requires linkage to Medicaid identifiers

<sup>&</sup>lt;sup>c</sup> The LME/MCO system is expected to no longer exist as of July 1, 2021

<sup>&</sup>lt;sup>d</sup> does not require assistance from DHHS for access

**Table 9: Measures** 

	Adams	Managemen	Data comme	Hood Co.
Measure Number	Measure	Measure Custodian	Data source	Used for hypotheses
1.	Getting Care Quickly	NQF #: 0006 / AHRQ	CAHPS	1.1
2.	Getting Needed Care	NQF #: 0006 / AHRQ	CAHPS	1.1
3.	Use of primary care services	Quality Strategy Objective 2.3	Claims / Encounters	1.1
4.	Adolescent Well-Care	NCQA – HEDIS 17168	Claims / Encounters	1.1
5. – 8.	Children and Adolescents' Access to Primary Care Practitioners (4 measures)	s' NCQA - HEDIS rimary tioners s)		1.1
9.	(Any) Annual Dental Visits	NQF#: 1388/ NCQA - HEDIS	Claims / Encounters	1.1
10.	Dental Sealants for Children at Elevated Caries Risk	NQF#: 2508/ NCQA – HEDIS / ADA	Claims / Encounters	1.1, 1.5
11.	Up to date on Childhood Immunizations	NQF#: 0038 / NCQA - HEDIS	Claims / Encounters/ immunization registry	1.1, 1.4
12. – 13.	Immunizations for Adolescents (2 measures)	NQF#: 1407 / NCQA - HEDIS	Claims / Encounters/ immunization registry	1.1, 1.4
14.	Customer Service	NQF #: 0006 / AHRQ	CAHPS	1.1
15.	Rating of Health Plan	NQF #: 0006 / AHRQ	CAHPS	1.1
16.	Rating of all Health Care	NQF #: 0006 / AHRQ	CAHPS	1.1
17.	Rating of Personal Doctor	NQF #: 0006 / AHRQ	CAHPS	1.1
18.	Adult BMI Assessment	NQF#: 0023 / NCQA - HEDIS	Claims / Encounter Data; PHP data	1.1
19.	Weight Assessment and Counseling for	NQF#: 0024/ NCQA - HEDIS	Claims / Encounter Data; PHP data	1.1, 1.4

Measure Number	Measure	Measure Custodian	Data source	Used for
Number	Nutrition and Physical Activity for Children/ Adolescents	Custodian		hypotheses
20.	Tobacco Use screening and follow-up	NQF# 2600	Claims / Encounter Data	1.1
21.	Breast Cancer Screening	NQF#: 2372 / NCQA - HEDIS	Claims / Encounter Data	1.1
22.	Cervical Cancer Screening	NQF#: 0032 / NCQA - HEDIS	Claims / Encounter Data	1.1, 1.4
23.	Flu vaccine for Adults age 18-64	NQF#: 0039 / NCQA - HEDIS	Claims / Encounter Data	1.1, 1.4, 1.5
24.	Appropriate Testing (for strep) for Children with Pharyngitis	NQF#: 0002 / NCQA - HEDIS	Claims / Encounter Data	1.1
25.	Appropriate Treatment for Children with Upper Respiratory Infection	NQF#: 0069 / NCQA - HEDIS	Claims / Encounter Data	1.1, 1.5
26.	Medication Management for People with Asthma	NQF#: 1799 / NCQA - HEDIS	Claims / Encounter Data	1.1, 1.4
27.	Asthma Medication Ratio	NQF#: 1800 / NCQA - HEDIS	Claims / Encounter Data	1.1, 1.4
28.	Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	NQF#: 0058 / NCQA - HEDIS	Claims / Encounter Data	1.1
29.	Annual Monitoring for Patients on Persistent Medications	NQF#: 2371 / NCQA - HEDIS	Claims / Encounter Data	1.1
30. – 31.	Pharmacotherapy Management of COPD Exacerbation	NQF#: 2856 / NCQA - HEDIS	Claims / Encounter Data	1.1

Measure	Measure	Measure	Data source	Used for
Number		Custodian		hypotheses
	(2 measures)			
32. – 33.	Statin Therapy for Patients with Diabetes (2 measures)	NQF#: 0547 / NCQA - HEDIS	Claims / Encounter Data	1.1
34.	Diabetes Screening for People with Schizophrenia or Bipolar Disorder who are Using Antipsychotic Medications	NQF#: 1932 / NCQA - HEDIS	Claims / Encounter Data	1.1
35. – 36.	Statin Therapy for Patients with Cardiovascular Disease (2 measures)	NQF#: 0543 / NCQA - HEDIS	Claims / Encounter Data	1.1
37.	Visits in the First 15 Months of Life	NQF#: 1392 / NCQA - HEDIS	Claims / Encounter Data	1.1
38.	Well-Child Visits in the Third, Fourth, Fifth, and Sixth Years of Life+	NQF#: 1516 / NCQA - HEDIS	Claims / Encounter Data	1.1, 1.4
39.	Concurrent Use of Prescription Opioids and Benzodiazepines	PQA	Claims / Encounter Data	1.1, 3.1
40.	Use of Imaging Studies for Low Back Pain	NQF#: 0052 / NCQA - HEDIS	Claims / Encounter Data	1.1
41.	Chlamydia Screening in Women	NQF#: 0033 / NCQA - HEDIS	Claims / Encounter Data	1.1
42.	Screening for pregnancy risk	NC Administrative Measure	Claims / Encounter Data	1.1
42.	Frequency of Prenatal Care (>=81% of expected visits)	NQF#: 1391 / NCQA - HEDIS	Claims / Encounter Data	1.1
43.	Prenatal and Postpartum Care+	NQF#: 1517 / NCQA - HEDIS	Claims / Encounter Data	1.1

Measure	Measure	Measure	Data source	Used for
Number		Custodian		hypotheses
44.	Pregnant smokers	NC Modified	Birth certificate / Claims	1.1
	screened and treated for tobacco use	measure	/ Encounter Data	
45.	All-Cause Hospital	NQF#: 1768 /	Claims / Encounter Data	1.1, 1.4
.5.	Readmission	NCQA - HEDIS	ciamis / Emodureer Bata	1.1, 1.1
46. – 47.	30-day hospital		Claims / Encounter Data	1.1
	readmission			
	rate following			
	hospitalization for			
48.	SUD or OUD	NOE#: 00E0 /	Claims / Encounter Data	1.1, 1.4
48.	Comprehensive Diabetes Care: HbA1c	NQF#: 0059 / NCQA - HEDIS	Claims / Encounter Data	1.1, 1.4
	poor control (>9.0) +	NCQA - HEDIS		
	poor control (* 5.0) ·			
49. – 57.	Comprehensive	NQF#: 0061,	Claims / Encounter Data	1.1
	Diabetes Care	0575, 0055 /		
	(9 measures)	NCQA - HEDIS		
58.	Diabetes	PQI-01, PDI-15	Claims / Encounter Data	1.1, 1.4
	Short-term			
	Complication Admission Rate			
59.	Controlling	NQF#: 0018 /	Claims / Encounter Data	1.1, 1.4
	High Blood Pressure	NCQA - HEDIS	ciamis / Encounter Data	1.1, 1.7
60.	COPD or Asthma in	PQI-05	Claims / Encounter Data	1.1, 1.4
	Older Adult			
	Admissions			
61.	Heart Failure	PQI-08	Claims / Encounter Data	1.1, 1.4
	Admissions			
62.	Receipt of	NQF#: 1334 /	Claims / Encounter Data	1.1
	Preventative Dental Services	CMS-416		
63.	Asthma Admissions in	PQI-15	Claims / Encounter data	1.1, 1.4
03.	Younger Adults	10113	ciaiiiis / Elicountei data	1.1, 1.4
64.	Gastroenteritis	PDI-15	Claims / Encounter data	1.1, 1.4
	Admissions		,	<i>,</i>
65.	Urinary Tract	PDI-18	Claims / Encounter data	1.1, 1.4
	Infection Admissions			
66.	Death rate by group		Claims / Encounter data	1.1
	(e.g.,		linked with death	
	SUD, SMI)		certificate data	

Measure	Measure	Measure	Data source	Used for
Number		Custodian		hypotheses
67.	Live Births Weighing	NQF#: 1382 /	Birth Certificate /	1.1
	Less than 2500	CDC (NC	Medicaid eligibility	
	Grams +	Modification)		
68.	Infant		Birth Certificate / Death	1.1
	Mortality		Certificate data	
69.	Healthy Days		BRFSS	1.1
70.	Tobacco Use Rate	Public Health	BRFSS / CAHPS	1.1
	(multiple measures)	Measures		
71.	Overweight / Obesity		BRFSS / CAHPS	1.1
	Rate			
72.	Death rate post		Death Certificate data	1.1
	prison release		linked with DOC data	
			and Medicaid	
			enrollment, claims, and	
			encounters	
73. – 74.	Antidepressant	NQF#: 0105/	Claims / Encounter data	1.2, 1.4
	Medication	NCQA - HEDIS		
	Management (two			
75.	measures)	NQMC: 004006	Claims / Engagnetar data	1.2
/5.	Depression screening	NQIVIC. 004000	Claims / Encounter data	1.2
	among those with SUD			
76. – 77.	Follow-up After	NQF#: 0576/	Claims / Encounter data	1.2, 1.4
70. 77.	Hospitalization for	NCQA - HEDIS	ciairis / Encounter data	1.2, 1.4
	Mental Illness or	TTEQT TIEDIS		
	Alcohol / Other Drug			
	Treatment+ (7/30			
	days)			
78. – 79.	Follow-up for	NQF#: 0108/	Claims / Encounter data	1.2, 1.4, 1.5
	Children Prescribed	NCQA - HEDIS		•
	ADHD Medication (2			
	measures)			
80.	Initiation and	NQF#: 0004/	Claims / Encounter data	1.2, 1.5, 3.1
	<b>Engagement of SUD</b>	NCQA - HEDIS		
	Treatment+			
81.	Medical Assistance	NQF#: 0027/	Claims / Encounters;	1.2, 1.4
	with Smoking and	NCQA - HEDIS	PHP data; CAHPS	
	Tobacco Use			
	Cessation			

Measure	Measure	Measure	Data source	Used for hypotheses 1.2	
Number 82.	Continuity of Pharmacotherapy with OUD	Custodian NQF#: 3175	Claims / Encounter data		
83.	Concurrent Use of Prescription Opioids and Benzodiazepines	PQA	Claims / Encounter data	1.2	
84. – 85.	ED visits for SUD- related diagnoses and specifically for OUD (2 measures)	NQF: 2605	Claims / Encounter data	1.2, 3.2	
86.	IP visits for SUD and specifically for OUD		Claims / Encounter data	1.2, 3.2	
87.	Adherence to Antipsychotic Medications for Individuals with Schizophrenia	NQF# 1879 NCQA - HEDIS	Claims / Encounter data	1.2, 1.5	
88.	Use of behavioral health care for people with SMI or SUD		Claims / Encounter data	1.2	
89.	Use of pharmacotherapy for opioid use disorder (OUD)	NQF 3400	Claims / Encounter data	1.3	
90.	Number of providers with DEA DATA 2000 waivers		DEA data	1.3, 3.2	
91.	Number of providers with DEA DATA 2000 waivers who have written prescriptions for Medicaid enrollees for MAT		DEA data and Claims/Encounter data	1.3, 3.2	
92.	Percent of SUD diagnosed beneficiaries who receive an SUD treatment service		Claims/Encounter data	1.3, 3.1	
93.	Long-Term Use of Opioids		Claims / Encounter data, CSRS	1.3, 3.2	

Measure	Measure	Measure	Data source	Used for
Number		Custodian		hypotheses
94.	Use of Opioids at High	NQF#:2940/	Claims / Encounter	1.3, 3.2
	Dosage in Persons	PQA	data, CSRS	
0.5	without Cancer	NOE!! 2050/	01: /5	4.2
95.	Use of Opioids from	NQF#:2950/	Claims / Encounter	1.3
	Multiple Providers in Persons Without	PQA	data, CSRS	
	Cancer			
96.	Reduced		DOC data	1.3
30.	incarceration for		DOC data	1.3
	drug-related charges			
97.	Number / % of		PHP data	1.4
<i>37</i> .	practices on the		iiii data	1.4
	PHP panel that			
	attest to being a level			
	3 AMH			
98.	Number of	Quality Strategy	Enrollment data	1.4
	enrollees	Objective 2.2		
	attributed to an	,		
	Advanced			
	Medical Home			
99.	Number of		Claims / encounters /	1.4
	enrollees receiving		enrollment	
	care management			
100.	Number of ED visits	NCQA - HEDIS	Claims/Encounter data	2.1
101.	Avoidable or	NYU / Billings	Claims/Encounter data	2.1
	preventable	algorithm		
	emergency			
	department visits			
102.	Number of hospital		Claims/Encounter data	2.1
	admissions			
103.	Number of hospital		Claims/Encounter data	2.1
404	days	ALIDO DOL d	Claire /Free classification	2.4
104.	Hospital admissions	AHRQ PQI and	Claims/Encounter data	2.1
	for ambulatory	PDI		
	sensitive conditions;			
	avoidable or			
	preventable inpatient			
105	hospitalizations Coordination of Care	NOE #+ 0006	CALIDS	າ າ
105.		NQF #: 0006	CAHPS	2.2
	(consumer perceptions)			
	μει τεμιίστιο)			

Measure Number	Measure	Measure Custodian	Data source	Used for hypotheses	
106.	Time to SDOH Screening from PHP attribution		Claims / Encounter data; PHP data; NCcare360	2.2	
107.	Enrollees Receiving Care Management during transitions in care	Enrollees Receiving Care Management during transitions in care	Claims / Encounter data; care management data systems	2.2	
108.	Medication Reconciliation Post- Discharge	Medication Reconciliation Post-Discharge	Claims / Encounter data	2.2	
109.	Total Expenditures to the Medicaid program and components		Claims / Encounter data	2.3, 3.3	
110.	Out-of-pocket costs to Medicaid enrollees		Claims / Encounter data	2.3, 3.3	
111.	Costs of Medicaid funded services and components		Claims / Encounter data	2.3, 3.3	
112.	Provider satisfaction	(under development)	Provider survey	2.4	
113.	Provider participation in Medicaid	(under development)	Claims / Encounter data	2.4	
114.	Percent of diagnosed beneficiaries who receive a treatment service		Claims / Encounter data	3.1	
115.	Death rate from overdose		Claims / Encounter data linked with death certificate data	3.2	
116.	Death rate from overdose post-release		Death Certificate data linked with DOC data and Medicaid enrollment, claims, and encounters	3.2	
117.	Percent of enrollees diagnosed with OUD receiving MAT	CMS	Claims / Encounter data	3.2	
118.	Percent of enrollees diagnosed with OUD		Claims / Encounter data	3.2	

Measure	Measure	Measure	Data source	Used for
Number		Custodian		hypotheses
	receiving non-			
	medication opioid			
	treatment services			

### E. Methodological Limitations

Our analysis approach uses distinct time periods to examine different phases of waiver activities, although in reality, these are not as distinct as would be ideal. Efforts to create a managed care waiver were initiated by North Carolina's General Assembly some time before the baseline time period incorporated here. If provider behavior changed as a result of expectations of upcoming changes, then our baseline period would not capture a true baseline, but rather a baseline under increasing expectation of managed care implementation. We will use breakpoint analysis to examine whether outcomes may have changed prior to key implementation dates to see if there may have been anticipation effects. An additional concern when using encounter data is how accurate and complete these data are, given that the incentives for complete reporting are dampened over fee-for-service claims. Any deficits in quality of encounter data would confound the PHP analyses, since they would be contemporaneous to the implementation of capitated care. The evaluation team will continuously monitor the quality of encounter data as the PHPs are implemented, following monitoring techniques used to monitor encounter data in the MAX data, for example. We will report any data quality concerns to NC DHHS as soon as they are discovered, in an effort to improve data quality as the demonstration continues. We will also compare trends in utilization measures from encounter data to similar measures in NC claims data (Medicaid and BCBSNC) as well as external data sources (e.g., trends in the MEPS and BRFSS data), although these sources tend to have a greater lag. Finally, the evaluation will not be able to assess all aspects of the Demonstration due either to data limitations or statistical limitations. For example, we will not have information on enrollees' labor market status and thus cannot evaluate whether improved services increase the ability of enrollees to participate in the labor market. We also may not have complete information on provider satisfaction and engagement for those providers who are not currently participating in the Medicaid program. As new providers begin serving patients through PHPs, we will have records of these interactions, but will not be able to capture information from providers who do not serve enrollees in any given year. In addition, if participation in AMHs is high, we may not be able to assess the impact of AMH participation using in-state controls. We will continuously seek ways to overcome these limitations throughout the evaluation period.

# **Attachment 1: Independent Evaluator**

As stated in the Special Terms and Conditions, the State is required to select an independent evaluator for the 1115 Waiver Evaluation. Key requirements for the evaluator are that the evaluator be free of any conflict of interest, have experience with large scale evaluations, have experience working with the necessary data sources and types to evaluate the waiver, and have expertise with the evaluation methodologies that will be needed to evaluate the waiver. Further, the evaluator must be able to conduct a fair and impartial evaluation and prepare an objective evaluation report. Considering these factors, the State selected the Cecil G. Sheps Center for Health Services Research at The University of North Carolina at Chapel Hill ('the Sheps Center') to conduct the evaluation. The Sheps Center has a long history over several decades working with North Carolina Medicaid data (claims, provider, and de-identified beneficiary) and other state data sources including from Divisions of Public Health/State Health Statistics and Mental Health, Substance Use Disorder, and Intellectual/Developmental Disabilities. A thorough conflict of interest investigation was undertaken at the university level, and each investigator from the Sheps Center team had to complete a multi-faceted conflict of interest questionnaire. The team was found to have no conflicts of interest and the report has been attached. Under a Master Data Use Agreement, the Sheps Center will have access to necessary data and stringent conflict of interest policies are in place to ensure the absence of conflict of interest in the evaluation.

#### Attachment 2: Conflict of Interest Statement



#### **Conflict of Interest Certification Form**

THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL

OFFICE OF THE VICE CHANCELLOR FOR RESEARCH CONFLICT OF INTEREST PROGRAM

BYNUM HALL, ROOM 301D 222 E. CAMERON AVENUE CAMPUS BOX 9103 CHAPEL HILL, NC 27599-9103

T 919.843.9953 F 919.843.9005 coi@unc.edu

Sponsor: North Carolina Department of Health and Human Services (NCDHHS)

Reference: Contract #38132

UNC-CH Title: NC 1115 Waiver Evaluation

UNC-CH Lead PI: Marisa Domino UNC CH Internal Reference: 18-5099

This letter is to certify that the University of North Carolina at Chapel Hill maintains a written policy and an administrative process for identification, evaluation and reporting of financial conflicts of interest meeting the requirements of Title 42 CFR Part 50, Title 42 CFR Part 94, Subpart F, NSF AAG Chapter IV.A, FAR 9.5 and other applicable federal regulations. Additionally, the Conflict of Interest Program at the University maintains a process of individual or organizational conflict of interest review which is responsive to any Sponsor's application or guidelines requesting this type of review.

Therefore, to the best of the Institution's knowledge and belief, it certifies:

### **ORGANIZATIONAL CONFLICTS OF INTEREST:**

There are no facts relevant to any possible sources of organizational conflict of interest (such as ownership or proprietary rights) in conducting the research as defined in the proposal guidelines.

#### INDIVIDUAL CONFLICTS OF INTEREST:

This section certifies that any individual team members of Institution, who will perform work as investigators under this project have completed the disclosure process and there is a conflict of interest to report, as defined in the proposal guidelines.

Dr. Pam Silberman, a co-investigator on this project, serves on the Board of Directors of Alliance Behavioral Healthcare, an entity subject to the policies evaluated in this project. The University has determined that the management for this relationship is as follows:

Disclosure in any public dissemination

Agreement and understanding that Dr. Silberman cannot discuss with Alliance Behavioral Healthcare (including but not limited to its Board, employees, volunteers), any on-going UNC research findings (such as what the policies are likely to be) until public dissemination of such policies.

If by some odd chance, the Alliance is used as an example or somehow brought into the policy or research discussion, Dr. Silberman would recuse herself from providing any commentary, opinion or analysis.

Page 1 of 2

Dr. Marisa Domino, the Principal Investigator at the University, is aware of the above conflict and the related management.

# **FUTURE CONFLICTS OF INTEREST:**

The individuals working on this project have been informed of their obligation to promptly report personal and/or organizational conflicts of interest to the Institution. The Institution will promptly report in writing to UNC-Chapel Hill's Award Specialist any organizational or individual conflicts of interest that may arise during the performance contract. The UNC-CH Award Specialist will coordinate any positive responses with the Sponsor.

By:		
Name: _	Joy Bryde	
Title:	Conflict of Interest Officer	
Date:	15 February 2019	

### **Attachment 3: Evaluation Budget**

The estimated budget for the Evaluation of the 1115 and SUD waivers is approximately \$1.5 million per demonstration year, running from May 1, 2019 – December 31, 2026, for a total of approximately \$10.7 million. This budget covers expenses relating to the quantitative and qualitative analysis using numerous sources of data and mixed methods approaches. This amount covers salaries, fringes, administrative costs, direct costs for travel around the state for primary data collection, conference calls amoung the study team, computing related expenses, and transcription and coding expenses. The qualitative component accounts for approximately \$1.8M while the quantitative component accounts for approximately \$5.7M of the budget. The remaining amount are for administrative or expenses shared by both the quantitative and qualitative components that are difficult to distribute. The total amount does not include the Evaluation of the Enhanced Case Management and Other Services Pilots nor of the provider survey, which have been budgeted separately.

The Cecil G. Sheps Center for Health Services Research at UNC-Chapel Hill will perform the 1115 and SUD waiver evaluation in partnership with NC DHHS. Sheps Center faculty and staff have decades of experience in policy evaluation, including mixed methods evaluations with claims data analysis, survey data fielding and analysis, and qualitative interview and focus group analysis. The multidisciplinary team has expertise on a number of dimensions important to this project, including behavioral health, CMS processes and procedures, Federal waivers, financial and economic analyses, administrative data analytics, organizational behavior, quality of care metrics, data visualization, implementation science, social determinants of health, and safety net providers.

# **Attachment 4: Timeline and Major Milestones**

Waiver Evaluation: Key Milestones

Activity	DY0	DY1	DY2	DY3	DY4	DY5	DY6	Post
Waiver Milestones								
Procure evaluation contractor								
Release RFP for standard plans								
SUD Component Implementation								
Implementation of standard plans								
Release RFP for tailored and specialized plans								
PHPs performance evaluated against Priority								
Measure Set								
Implementation of tailored and specialized								
plans								
<b>Evaluation Milestones</b>								
Contract for Evaluation Design		3/19						
Contract for Evaluation		5/19						
Hold regular meetings between DHHS and								
Evaluation team								
Collaborate on data sharing to facilitate								
evaluation								
Receipt of baseline claims and encounter data								
for the evaluation								
Calculation of Baseline Metrics								
Submit Draft Evaluation Design								
Receipt of PHP encounter data for evaluation								
Receipt of other secondary data sources								
including provider survey data and CAHPS								
Calculation and Monitoring of all Quantitative								
Metrics								
Submit Quarterly Progress Reports		9/19						
Submit Annual Report			1/20					
Submit Draft Interim Evaluation Report					11/21			
Submit Final Interim Evaluation Report								
Submit Draft Summative Evaluation Report								
Submit Final Summative Evaluation Report								
Submit Final Reports to DHHS								

DY=Demonstration Year

DYO are activities that occurred prior to the implementation of the waiver

DY1= 1/1/2019 - 10/31/2019

DY2=11/1/2019 - 10/31/2020

DY3=11/1/2020-10/31/2021

DY4=11/1/2021 - 10/31/2022

DY5=11/1/2022 - 10/31/2023

DY6=11/1/2023 - 10/31/2024

Post period extends beyond the end of DY6 for analysis only, pending any renewal or continuation of the waiver.

# **Attachment 5: Abbreviations Used**

AMH Advanced Medical Home

CMS Centers for Medicare & Medicaid Services
CSRS Controlled Substances Reporting System

DOC Department of Corrections

FFS Fee-for-service

I/DD Intellectual / Developmental Disability

IMD Institute for Mental DiseaseMAT Medication-Assisted Treatment

OUD Opioid Use Disorder
PHP Prepaid Health Plan
SUD Substance Use Disorder